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INTRODUCTION 
 
Prologue 
 
The concept of an integrated and tightly regulated multicellular response in 
pathological processes in general, and inflammation in particular, has been applied to several 
organs and tissues, but only very recently this concept has been considered in the gut. There 
is a remarkable paucity of information on cellular interactions in complex inflammatory 
diseases, such as Crohn’s disease (CD) and ulcerative colitis (UC), and there are essentially 
few data derived from animal models of inflammatory bowel disease (IBD). This makes it 
difficult to understand the cellular and molecular mechanisms underlying gut inflammation in 
human. Intestinal inflammation has traditionally been viewed as a process in which effector 
cells cause the destruction of other mucosal cells that behave as passive bystander targets 
(Fiocchi, 1997b). 
According to the Crohn’s and Colitis Foundation of America (CCFA), up to one million 
Americans suffer from IBD, with approximately 30 000 new cases diagnosed each year. Males 
and females appear to be affected equally. CD may occur in people of all ages, but it is 
primarily a disease of the young adult. Most cases are diagnosed before age 30, although a 
much smaller number of patients may develop the disease between the ages of 50 and 70 
(http://www.ccfa.org). 
Moreover, CD tends to occur in families and certain ethnic groups. Studies have shown 
that about 20 to 25 percent of patients may have a close relative with either CD or UC. It has 
been estimated that approximately five to eight percent of patients with CD may have a first-
degree relative (brother, sister, parent, or child) with IBD. This does not seem to be any clear-
cut pattern to this familial clustering, and the inheritance patterns are probably very complex. 
Researchers are actively attempting to establish a link to specific genes that may govern the 
transmission of the disease. The data suggest that more than one gene may be involved 
(Bonen and Cho, 2003). 
At present, there is a lack of information on human gastrointestinal (GI) inflammatory 
diseases, regarding the specific genes involved. The present project aims to tackle this issue 
by finding new answers that may help in the treatment of individuals who are afflicted with or 
are at risk for GI inflammatory diseases.  
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Gastrointestinal physiology 
 
General Functions of the Gastrointestinal (GI) Tract 
The GI system provides the body with a continual supply of water, electrolytes, and 
nutrients. The process of food reduction occurs in five main phases: ingestion, fragmentation, 
digestion, absorption and elimination. To achieve these requirements, the alimentary tract 
exhibits typical layers for the better absorption of the nutrients. Figure 1 shows a cross section 
of the intestinal wall, including the layers from the outer surface inward: (1) the serosa, (2) the 
longitudinal muscle layer, (3) a circular muscle layer, (4) the submucosa, and (5) the mucosa. 
The mucosa is divided in three layers: an epithelial layer, a connective tissue layer 
called lamina propria, and a fine smooth musculature layer, the muscularis mucosae, which 
causes local movements of the mucosa. The submucosa is a connective tissue layer that 
maintains the mucosa and which contains large blood vessels, lymphatic and nerves. The 
muscular propria is formed by smooth muscles that generally are subdivided in two 
histological layers: an internal circular layer and a longitudinal external layer. The action of 
these smooth muscular layers, placed in perpendicular angles to each other, is the bases of 
the peristaltic contraction.  
The food passes through the GI tract by the action of two mechanisms: (1) the 
voluntary muscular action of the oral cavity, the pharynx, and the superior third of oesophagus 
(2) following of the appearance of involuntary contraction waves of the smooth musculature, 
the peristaltic. The latter and the secretory activity of all digestive tract are regulated by the 
autonomous nervous system and diverse hormones, some of which are secreted by the 
endocrines cells located within the own tract. Due to its continuity to the exterior, the GI tract is 
a potential entrance for pathogenic organisms. For this reason, the system incorporates a 
certain amount of defensive mechanisms between which are important lymphoid tissue 
aggregates distributed through the entire alimentary tract. 
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Figure 1: Typical cross section of the gut 
(http://medweb.bham.ac.uk/research/toescu/Teaching/GIT/StrucWall.gif) 
 
The “splanchnic circulation” 
The splanchnic circulation includes the blood flow through the gut, spleen, pancreas, 
and liver. The blood that courses through the gut, spleen, and pancreas flows immediately into 
the liver by way of the portal vein. In the liver, the blood circulates through millions of sinusoids 
before leaving it by way of the hepatic veins that empty into the vena cava of the general 
circulation (Fig. 2). This is the secondary flow of the blood through the liver and it affords the 
reticuloendothelial cells that line the liver sinusoids to remove bacteria and other harmful 
agents that might enter the general blood stream from the GI tract. 
The liver sinusoids also receive most of the non-fat, water-soluble nutrients absorbed 
from the gut. In addition, reticuloendothelial and hepatic cells absorb and store temporarily half 
to three quarters of all absorbed nutrients. The fat-based nutrients are absorbed into the 
intestinal lymphatics which are then conducted to the circulating blood by way of the thoracic 
duct, bypassing the liver. 
Under normal conditions, the blood circulates in each area of the GI tract, including all 
layers of the gut wall. The local activity of the gut is directly related to the level of blood that 
flows into each intestinal vessel. For instance, after a meal, the motor, secretory and 
absorptive activities are increased; likewise the blood flow increases extremely but reduces to 
the resting level over another 2 to 4 hours. The blood flow in the villi and adjacent regions of 
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the submucosa is also increased during active absorption of nutrients (Vanner and 
Surprenant, 1996).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The gastrointestinal circulation 
(http://abdellab.sunderland.ac.uk/Lectures/Nurses/pics/anatomy/LiverBile.html) 
 
Features of the intestine 
The small intestine is mainly involved in the absorption of nutrients via a vast surface, 
approximately four or six meters in length in a man. In addition, the disposition of the mucosa, 
forming numerous projections, called villous and the presence of invaginations between the 
bases of the villous towards the interior of the crypts (called Lieberkuhn’s crypts) also increase 
the absorption (for review see Kaminsky and Zhang, 2003).  
The intestinal villous are covered by a simple cylindrical epithelium which is continued 
with the epithelium of crypts. This epithelium is formed by the enterocytes, which are high 
cylindrical cells with a basal nucleus, and by the caliciform cells, which are distributed between 
the enterocytes. The intestinal epithelium renews completely every three-five days due to its 
continuous cells flaking that are located in the end of the villous, towards the intestinal light. 
The mitotic activity is made into the crypts in where the cells mature before degenerating and 
being eliminated in the end of the villous (Okamoto and Watanabe, 2004).  
A third cellular type, that lacks digestive or absorbent properties, is located in the base 
of the crypts. These cells, called Paneth’s cells, are loaded of intensely eosinophiles grains, 
and constitute a characteristic detail of the human small intestine, because in some mammals 
they do not exist. The Paneth’s cells constitute a stable population and has ultra-structural 
characteristics of exocrine cells - secretors of proteins, although its complete function is not 
clarified. 
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Gastrointestinal Immunology 
 
Intestinal epithelial cells and their function in the mucosal immune system 
Intestinal epithelial cells are the first cells to come into contact with luminal antigens 
present in the intestinal microflora. They compose a barrier that separates the internal host 
from the external environment. Enterocytes also have an important role in fluid absorption and 
secretion as well as ion transport. These features of the intestinal epithelial cells are aided by 
intercellular tight junctions that restrict the passage of even small molecules (2 kDa) 
(Clayburgh et al., 2004). Moreover, epithelial cells at mucosal surfaces are an integral and 
essential component of the host’s innate and acquired immune system. They constantly 
interact with invasive and non-invasive pathogens and adjacent and underlying cells in the 
mucosa by generating and transmitting signals. Thus, these cells constitutively express, or can 
be induced to express molecules involved in antigen presentation such as HLA class I and 
class II molecules (Mayer et al., 1991); complement components such as C3, C4, factor B 
(Andoh et al., 1993); several receptors for cytokines including interleukin (IL)-2, IL-4, IL-6, 
interferon (IFN)-γ, and tumor growth factor (TGF)-β1 (Ullmann et al., 1992; Reinecker and 
Podolsky, 1995; Mulder et al., 1990; Raitano and Korc, 1993); eicosanoids (e.g. prostaglandin 
E2 (PGE2) in Laurent et al., 1998); and an array of pro-inflammatory cytokines and 
chemokines, i.e. tumor necrosis factor (TNF)-α and IL-8 (Eckmann et al., 1993a; Fierer et al., 
1993; Jung et al., 1995; Dwinell et al., 1999). This “communication network” is finely regulated 
to induce or repress immune and inflammatory responses at mucosal surfaces. Such 
interaction involved the contact of epithelial cells to antigens causing the expression and 
production of cytokines. These affect other epithelial cells through an autocrine or paracrine 
effect and stimulate intestinal epithelial lymphocytes in the paracellular space and other 
immune cells such as neutrophils, mononuclear phagocytes, T cells, mast cells or eosinophils 
to release mediators that act on epithelial cells themselves as well as other cell population 
within the lamina propria (Maaser and Kagnoff, 2002).  
 
Interactions occurring between bacteria and the different cell types of the 
immune system 
The mucosal immune system needs to distinguish between “pathogenic” and “non-
pathogenic” molecules. This immunological barrier is maintained by several mechanisms, 
including the degradation of potential immunogenic substances to low- or nonantigenic 
particles, and a constant communication between intestinal bacteria and different cell types of 
the immune system. The innate immune system exerts a permanent defence by stimulating 
the production of a mucus layer, by secreting antibacterial peptides and by maintaining the 
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integrity of the tight epithelium (Xavier and Podolsky, 2005). A breakdown of this controlled 
system results in bacterial invasion with subsequent intestinal infection or even in autoimmune 
pathogenesis such as CD or UC (Fiocchi, 1997a). 
To avoid that soluble proteins and microbes do constantly cross the epithelium, the 
intestinal immune system used an elegant alternative to undergo an infection known as 
antigen presentation. This process involves the degradation of proteins to peptides that are 
associated with either major histocompatibility complex (MHC) class I or II molecules at the 
surface of antigen-presenting cells (APC). The latter express both MHC class I and class II 
molecules in addition to the ability to activate both CD8+ and CD4+ T cells.  
The epithelium is interspersed in some regions by specialized cells, which do not 
present the brush border glycocalix on the apical cell surface. These cells, known as M cells, 
possess the microfolds instead of the brush border and have a huge invagination of the 
basolateral membrane, forming a pocket containing lymphocytes and/or macrophages. The 
lack of the brush border might facilitate the access and adherence of luminal antigens, while 
the basolateral membrane of M cells interacts with cells of the mucosal immune system. 
Found primarily in the Peyer’s patches in the distal ileum of the small intestine, M cells use the 
transepithelial vesicular transport to carry antigens from the mucosal surface to specialized 
APCs in the underlying gut-associated lymphoid tissue (GALT) where they are presented to 
the immune system (Nagler-Anderson, 2001; Makala et al., 2004). M cells do not express 
MHC class II antigens and, therefore, they are unlikely to function as a professional APC 
(Beagley and Elson, 1992). 
Another cell type capable of transporting antigens across the epithelium is the 
dendritic cell (DC). These cells are located in lymphoid as well as non-lymphoid tissues 
including sites of antigen entry. They are professional APC and use their dendrite-like process 
to sample antigens directly through epithelial tight junctions. During this process, the integrity 
of the epithelium is unaltered due to the rapid re-formation of the tight junctions by proteins 
expressed on both enterocytes and DCs (Nagler-Anderson, 2001). DCs process and complex 
antigens to MHC class II molecules which is then presented to T cells, eliciting an active 
immune response (Liu and MacPherson, 1993). This occurs due to the fact that DCs express 
molecules important to the T cell activation i.e. antigenic peptide, MHC class II and 
co-stimulatory molecules such as CD86, CD80 and CD40 (Sundquist et al., 2004). DCs exist 
in three stages of development: (1) precursor DC found in the blood and lymphatics, (2) 
tissue-residing immature DC, and (3) mature DC present within secondary lymphoid organs. In 
the absence of inflammatory stimuli or microbial products, DCs are in an immature state with 
high capacity to capture and process antigens and poor capacity to stimulated naïve T cells. 
However, after the contact with an antigen on the periphery or signals derived from 
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substances associated with infection or inflammation (e.g. lipopolysacharide (LPS), IL-1β, 
TNF-α), immature DC transform into mature DC with an exceptional capacity to stimulate 
T cells, particularly naïve T cells. This maturation step occurs on the way to lymphoid organs, 
when they are carrying encountered antigen (Makala et al., 2004). The migration of DCs from 
inflamed tissues to secondary lymphoid organs is mediated by chemokines. The dendritic cell-
population can be divided in subgroups depending on the expression of other surface 
molecules, including CD8α, CD4, CD11b and CD205 (Sundquist et al., 2004).  
Macrophages are also found in a large number in the GI tract and are the first 
phagocytic cells of the innate immune system that interact with microorganisms and their 
products that have penetrated the epithelium. They are predominantly located in the 
subepithelial lamina propria in the small and large intestine (Smythies et al., 2005). In addition, 
these cells are also present in the dome region of Peyer’s patches (Hume et al., 1987). 
Intestinal macrophages have two important functions: (1) to protect the host against foreign 
pathogens and (2) to regulate mucosal responses to commensal bacteria. Human lamina 
propria macrophages express surface markers including MHC class II, CD13 (aminopeptidase 
N), CD68 and CD74 (invariant chain), and HLA-DR. However, intestinal macrophages do not 
express innate response receptors such as receptors for LPS (CD14), Immunoglobulin (Ig) A, 
IgG, CR3 and CR4, receptors for IL-2 and IL-3, and the integrin LFA-1 (Smythies et al., 2005). 
Resident tissue macrophages can be activated under the influence of various cytokines, which 
can modify their morphology, function, and metabolism. These changes reflect an increased 
capacity to enter tissues, phagocytose, and kill microorganisms and tumor cells in addition to 
an increased capacity for producing and secreting several mediators and cytokines including 
TNF-α, IL-1, IL-6 and IL-8. IFN-γ is considered to be the most important macrophage activator, 
inducing a vast array of phenotypic and functional changes not only on macrophages but also 
on other cells. It is produced by T cells, natural killer (NK) cells and probably by macrophages 
themselves (Boehm et al., 1997). 
Intestinal epithelial cells are also able to function as APC. Some reasons for this is 
that these cells are poorly phagocytic and constitutively express or can be induced to express 
MHC class II molecules in addition to process and present antigens to primed T cells (Kagnoff 
and Eckmann, 1997). In a conventional antigen-presenting system, APC activate CD4+ helper 
T cells. In contrast, intestinal epithelial cells stimulate CD8+ suppressor T cells either by direct 
activation or by secretion of soluble factors, indicating that enterocytes play an important role 
in the down-regulation of mucosal immune responses (Toy and Mayer, 1996). In addition, 
epithelial cells produce a number of cytokines that affect immunoregulation and express 
cytokine receptors which can alter APC function (Madara and Stafford, 1989; Deem et al., 
1991; Ciacci et al., 1993). 
  Introduction 
  21  
Spahn and Kucharzik presented an excellent overview of the lymphoid elements of the 
gut associated lymphatic system and their interaction in this cell communication network as 
shown in Figure 3. 
 
Figure 3: The lymphoid elements of the gut associated lymphatic system  
There are three possibilities to take up luminal antigens: (A) through the intestinal epithelial cells (IEC), non-
professional APC; (B) by lamina propria dendritic cells (DC); and by specialized epithelial cells (C) the M cells. 
Peyer’s patches (PP) and mesenteric lymph nodes (MLN) represent the organized intestinal lymphoid follicles. The 
arrows demonstrate the lymph flow direction which goes from PP and villus lamina propria to the MLN (Spahn and 
Kucharzik, 2004). 
 
Mucosal lymphocyte trafficking 
Lymphocytes are distributed through the entire intestinal wall and are an important part 
of the mucosal immune system. The latter has three types of lymphocytes: (1) intraepithelial 
lymphocytes (IEL) which reside between mucosal epithelial cells, above the basement 
membrane; (2) lamina propria lymphocytes (LPL) and are located beneath the IEL layer, in the 
lamina propria between the epithelium and submucosa; and finally, (3) cells of the organized 
lymphoid tissue in the Peyer’s patches (PP). This layer is found predominantly in the small 
intestine, appendix (solitary lymphoid nodules present in the colon and ileum) and MLN 
(James, 1991; Simecka, 1998). IEL and LPL are the largest single T cell sites in humans while 
PP lymphocytes are much less prominent in humans than in rodents.  
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IEL in humans are predominantly T lymphocytes and the majority have the CD8 
phenotype, carrying either the αβ or the γδ T-cell receptor for antigens. Mouse and human 
small and large intestinal IEL comprise much higher percentages of γδ T cells than are found 
in other lymphoid sites. Depending on the type of response needed, the composition of IEL is 
affected by their location along the intestine. An example for that is the difference in bacteria 
species found in the large compared to the small intestine. The former has a vast number of 
bacteria of many species present in its flora. γδ T cells, which are abundant in the colon 
epithelium of the mucosa, participate in immune defence, immune regulation and tissue 
homeostasis (Ullrich et al., 1990; Makala et al., 2004). Moreover, intraepithelial γδ T cells are 
involved in immune reactions in mucosal tissues by producing an array of pro-inflammatory 
cytokines and chemokines (Makala et al., 2004). Since a large number of IEL reside in the 
intestinal epithelium, a cross-talk between epithelial cells and IEL is essential for mucosal 
immune responses. The expression of IL-7 by enterocytes, for example, is important for the 
development of IEL (Nagler-Anderson, 2001) while intraepithelial γδ T cells modulate growth 
and differentiation of epithelial cells (Boismenu and Havran, 1994). 
LPL are predominantly T cells with both CD4+ (Beagley and Elson, 1992) and CD8+ 
(James, 1991) phenotypes, expressing αβ T-cell receptor heterodimers (Fujihashi et al., 
1994). These cells express activation markers, including the receptor for IL-2 (IL-2R+) - 
responsible for the proliferation, differentiation, and function of CD4+ cells (James et al., 1987) 
- and MHC class II (Zeitz et al., 1988). LP T cells are a specialized memory phenotype, 
implying that these cells already have been in contact with an antigen. Intestinal naïve T cells 
interact with antigens in organized lymphoid tissues (PPs and lymphoid follicles in the colon), 
differentiate, mature and enter the peripheral circulation. From the blood, activated 
lymphocytes home back to the LP as memory T cells (Jalkanen et al., 1989; Jalkanen, 1991). 
The activation of LP T cells is probably the result of the continuous antigenic and mitogenic 
challenge of the gut lumen. Intestinal LPLs have important functions in the gut: (1) CD4+ T 
cells help B-cell immunoglobulin (Ig) synthesis, mainly for the synthesis of IgA - the 
predominant type of Ig secreted by B lymphocytes of the gut – by producing cytokines such as 
IL-2, IL-4 and IFN-γ. (2) CD8+ T cells function as suppressors for Ig production (Lee et al., 
1988). In addition to ligand-receptor interactions with other lymphocytes, LPL responses are 
also regulated by intestinal epithelial cells. The latter produce cytokines such as IL-8 and 
MIP-3α which directly affect polymorphonuclear cells and lymphocytes (Eckmann et al., 
1993a; Izadpanah et al., 2001). These chemokines recruit neutrophils and lymphocytes, 
respectively, to the inflamed tissue.  
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Finally, lymphocytes are also found in PP, lymphoid aggregates that extend through 
the mucosa and submucosa of the small and large intestine. The surface covering the dome 
region of PP is the specialized follicle-associated epithelium, containing antigen-sampling M 
cells (already described above). The latter functions as “gateways to the immune system”, 
delivering antigens to APCs present in the PP subepithelial dome. The major sites for B cells 
are located in the B-cell follicles, a central region of the PP beneath the layer of M cells. This 
region is surrounded by DC. Primed T helper cells, migrating through this region, are able to 
interact with B cells associated with follicular DC, leading to Ig production. However, 
differentiation and maturation of IgA responses occur only after activated B cells leave the PP. 
Mature T cells are present in parafollicular regions of PP, in the periphery of the B cell follicles, 
and their activation is pivotal for the regulatory and effector activities of the immune system. 
T cells are also found near to the specialized epithelium where antigen presentation by 
macrophages and DC can occur. Moreover, CD4+ T helper cells and cytotoxic T lymphocytes 
are activated within PP and subsequently can migrate to other sites, such as the LP or 
intestinal epithelium (Kagnoff, 1993; Simecka, 1998; Nagler-Anderson, 2001; Makala et al., 
2004).  
 
Mucosal cytokine/chemokine production by intestinal epithelial cells 
Inflammation is the most common type of response to microbial invasion or injury. The 
GI tract with its enormous mucosal surface is clearly more susceptible to such inflammatory 
responses. It is continuously exposed to a myriad of antigenic, mitogenic, mutagenic and toxic 
stimuli. The constant interaction of microorganisms with mucosal surfaces and the overlying 
epithelial cells can cause epithelial barrier disruption, and therefore, an acute inflammatory 
response. Inflammatory cells, including macrophages, neutrophils, and lymphocytes, are 
recruited into the inflammatory site.  
Intestinal epithelial cells have the ability to present antigens to mucosal T cells in 
addition to produce cytokines in response to their environment. They produce cytokines that 
regulate the proliferation of intestinal LPL (Watanabe et al., 1995) and express functional 
cytokine receptors for several T cell-derived cytokines (Reinecker and Podolsky, 1995). This 
reciprocal exchange of regulatory signals is altered during intestinal inflammation, where 
epithelial cells express or up-regulate the expression of several functional cytokines and cell 
adhesion molecules (Huang et al., 1996). They also secrete a variety of pro-inflammatory 
cytokines affecting the leukocyte activity (Jung et al., 1995). 
Recent in vivo studies have provided a number of evidences that cytokines and 
chemokines are crucial mediators of inflammatory responses and tissue injury in intestinal 
inflammation (Ajuebor and Swain, 2002). Intestinal epithelial cells produce a range of 
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pro-inflammatory cytokines, including IL-1α, IL-1β, IL-6 and TNF-α, and chemokines. These 
are a large family of small molecules (7-15kDa) that participate in immune and inflammatory 
responses by chemoattracting and activating polymorphonuclear leukocytes (PBL) to the 
injured tissue (Baggiolini et al., 1994; Baggiolini, 1998; Luster, 1998). Based on the 
arrangement of their N-terminal cysteine residues, chemokines are subdivided into four 
classes: C, CC, CXC, and CX3C. Their biological action are mediated through 7-
transmembrane G protein-coupled receptors present on the surface of target cells (Balkwill, 
1998; Luster, 1998; Murphy et al., 2000). IL-8, growth regulated oncogene (GRO)-α, GRO-γ, 
macrophage inflammatory protein (MIP)-2 and IFN-inducible protein (IP)-10 belong to the CXC 
chemokine subfamily and recruit mainly neutrophils to the inflamed tissue (Cuenca et al., 
1992; Eckmann et al., 1993a; Eckmann et al., 1993b; Izadpanah et al., 2001; Kwon et al., 
2002). MIP-3α, a member of the CC chemokines, recruits monocytes/macrophages and 
subpopulations of T cells (Yang et al., 1997; Dwinell et al., 1999; Ajuebor and Swain, 2002). 
Regulated on activation normal T cell expressed and secreted (RANTES), a chemoattractant 
for T cells and eosinophils, is also expressed by intestinal epithelial cells (Yang et al., 1997). 
The secretion of these chemokines by activated epithelial cells suggest that - in addition to 
orchestrating the initiation of mucosal inflammatory and immune responses - these cells have 
an important function in initiating the mucosal influx of inflammatory cells (Kagnoff and 
Eckmann, 1997; Dwinell et al., 1999).  
Epithelial cells produce IL-1 mRNA; however, the intracellular protein levels are very 
low. It was suggested that IL-1 would act on adjacent cells to induce or amplify an 
inflammatory response or induce wound healing (Eckmann et al., 1995). TNF-α is also 
produced by epithelial cells in response to bacteria invasion or an extern stimuli (Keshav et al., 
1990; Tan et al., 1993), leading to increased production and activation of other 
pro-inflammatory cytokines (e.g. IL-8, MIP-3α and TNF-α itself) and factors that promote 
intestinal inflammation (Neurath et al., 1997; Van Deventer, 1997). It also acts on the intestinal 
epithelium altering the epithelial barrier function by disrupting the intercellular tight junctions of 
the enterocytes (Ma et al., 2004). Furthermore, intestinal epithelial cells have the potential to 
produce the pro-inflammatory cytokine IL-6 indicating its importance in mucosal inflammatory 
responses (Akira et al., 1993). There are no data related to the expression of IL-2, IL-4, IL-5, 
IL-12, or IFN-γ by intestinal epithelial cells. This suggests that cytokines secreted by these 
cells are more involved in initiating and regulating the innate mucosal inflammatory responses 
rather than antigen-specific mucosal immune responses (Kagnoff and Eckmann, 1997). 
Epithelial cells also express receptors for several cytokines (e.g. IFN-γ, IL-1, TNF-α, TGF-β1; 
IL-2, IL-4, IL-7 and IL-9), which is an indicative that they respond to a range of signals from the 
underlying mucosa (Reinecker and Podolsky, 1995).  
  Introduction 
  25  
Enterocytes express mediators involved in inflammatory responses 
Intestinal epithelial cells produce several mediators involved in inflammation. One of 
them is the COX-2-dependent prostaglandin E2 (PGE2), which is increased in intestinal 
inflammation. After bacteria invasion or extern stimuli, TNF-α stimulates the expression of 
COX-2, the key enzyme for PGE2 formation. The latter can directly induce epithelial cells to 
increase chloride secretion (Eckmann et al., 1997) and indirectly stimulate enteric nerves to 
release neurotransmitters that activate epithelial ion transport (Eberhart and Dubois, 1995). 
COX-2 was shown to be also expressed in surface epithelial cells in inflamed areas of CD and 
UC (Singer et al., 1998). 
During chemokine-dependent recruitment of inflammatory cells into the mucosa, 
intestinal epithelial cells can interact with neutrophils and lymphocytes by expressing ICAM-1. 
Its ligand β2 integrin is expressed on neutrophils and lymphocytes. ICAM-1 is up-regulated on 
epithelial cells after bacterial invasion or stimulation with pro-inflammatory cytokines, including 
IFN-γ, IL-1β and TNF-α (Kelly et al., 1994). Thus, lymphocyte-enterocyte interactions are 
enhanced in intestinal inflammation (Brynskov et al., 1992). The function of ICAM-1 on the 
apical surface of intestinal epithelial cells is to maintain neutrophils that have closely 
transmigrated through the epithelium (Huang et al., 1996). 
Another mediator found in intestinal epithelial cells during the course of intestinal 
inflammation is nitric oxide (NO). It is produced by the inducible NO synthase (NOS2) and 
affects multiple gastrointestinal functions, including blood flow and mucosal inflammation 
(Kagnoff and Eckmann, 1997).  
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Inflammatory bowel disease (IBD) 
 
IBD includes two intestinal inflammatory disorders: Crohn’s disease (CD) and 
ulcerative colitis (UC). In CD, the intestinal area affected comprises commonly the lower ileum; 
however, the disease can flare up anywhere, including the colon. Interestingly, “patches” of 
normal tissue can be found between affected areas. In contrast, UC is characterized by 
contiguous inflammation of the colonic lamina propria without “patches” of normal tissue 
between injured areas. Both CD and UC are dependent on genetic and environmental factors 
(Podolsky, 1991) and are characterized by prominent ulcerative lesions and a huge leukocyte 
infiltration in the bowel wall. CD and UC are associated with a Th1 and Th2 immune 
responses, respectively. In CD a huge amount of T cells infiltrate the intestinal mucosa, while 
in UC neutrophilic infiltration prevails (Fiocchi, 1998). Table 1 resumes some features of both 
CD and UC. 
 
Table 1. Features of CD and UC 
Component CD UC 
Environmental factors Detrimental effect of smoking Beneficial effect of smoking 
 Symptoms improved by 
selected diets 
No beneficial effect of diet 
 Increased intestinal 
permeability in healthy 
relatives 
Normal intestinal permeability 
in healthy relatives 
Genetic associations Largely different from UC Largely different from CD 
Microbial agents Important role of bacterial flora Limited role of bacterial flora 
 Some association with 
measles virus and M. 
paratuberculosis 
No association with measles 
virus and M. paratuberculosis 
Humoral immunity Moderate antibody secretion Prominent antibody secretion 
 Limited evidence for 
autoimmunity 
Evidence for autoimmunity 
 Weak association with 
antineutrophil cytoplasmic 
antibodies 
Strong association with 
antineutrophil cytoplasmic 
antibodies 
Cell-mediated immunity Prominent T-cell infiltration in 
the mucosa 
Prominent neutrophil 
infiltration in the mucosa 
  Introduction 
  27  
 Hyperreactive T cells Normal/hyporeactive T cells 
 Resistance of T cells to 
apoptosis (?) 
Normal T-cell apoptosis (?) 
Cytokines and 
mediators 
Moderate production of 
eicosanoids 
Prominent production of 
eicosanoids 
 Th1-like profile Th2-like profile 
 Increased cytokine production 
in involved and uninvolved 
mucosa 
Increased cytokine production 
limited to involved mucosa 
 
Table was adapted from (Fiocchi, 1998). 
 
Many cytokines and chemokines are markedly increased in intestinal tissues from 
patients with CD and UC. Expression levels of IL-1β, IL-6, TNF-α, and IFN-γ in the colonic 
tissue from patients with IBD was shown to be elevated (Rogler and Andus, 1998). In addition, 
this increase was shown to play an important role in sustaining inflammatory responses in 
animal models (Elson et al., 1995; Strober et al., 2002). IL-8 levels were increased in rectal 
biopsies from patients with active CD or UC (Mahida et al., 1992; Izzo et al., 1993; Ajuebor 
and Swain, 2002). Subsequently, the expression of this chemokine was correlated with the 
severity of inflammation found in IBD (Mazzucchelli et al., 1994). During the active phase of 
IBD, IL-8 expression is also increased in neutrophils and macrophages in addition to intestinal 
epithelial cells (Ajuebor and Swain, 2002). Consistent with these findings is the increased 
expression of CXCR1, the receptor for IL-8, on macrophages and neutrophils of patients with 
active UC (Williams et al., 2000). This suggests that the role of IL-8 during chronic colitis is to 
attract CXCR1-bearing inflammatory cells to colonic tissue, where activation of these cells 
leads to tissue ulceration. 
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Plant extracts affect GI inflammation 
 
Many dietary plants and their phytochemicals possess anti-inflammatory properties. 
Among them, Boswellia serrata and its boswellic acids, EGCG from green tea, and curcumin 
from turmeric have been shown to inhibit inflammatory processes in a variety of models, as 
described in the following chapters of this thesis. Other natural plants have also been shown 
to affect intestinal inflammation, including Allium sativum (garlic), Plantago ovata seeds, 
Polygalae root, Ispaghula husk, Polygonum tinctorium, and germinated barley foodstuff. Garlic 
extract ameliorated inflammation associated with IBD by inhibiting Th1 and inflammatory 
cytokine production (e.g. IL-12, IFN-γ, TNF-α, and IL-8) and up-regulating the synthesis of the 
anti-inflammatory cytokine IL-10 (Hodge et al., 2002). In another study, seeds of Plantago 
ovata were shown to be efficient in maintaining remission in UC. Furthermore, their effect was 
comparable to mesalamine, a drug used in the treatment of colitis. It was demonstrated that 
colonic fermentation of the Plantago ovata seeds yields butyrate, a short-chain fatty acid 
(SCFA) which serves as nutrient for intestinal epithelial cells. The presence of butyrate in IBD 
reduced inflammation by inhibiting the production of cytokines and the activation of the 
transcription factor nuclear factor – kappa B (NF-κB) (Fernandez-Banares et al., 1999). In 
addition, butyrate protects the intestinal mucosa against injury and promotes mucosal healing 
(Scheppach et al., 1992). Moreover, husk of the Plantago ovata seeds, also known as 
Ispaghula husk, was shown to efficiently alleviate GI symptoms in quiescent UC in humans 
(Hallert et al., 1991). In an animal model of colitis, Polygalae senega root reduced the degree 
of inflammation by regulating the associated-cytokine production of IEL (mainly IFN-γ and IL-4) 
and diminishing PBL infiltration (Hong et al., 2002b). Prebiotic products have also been 
studied in IBD. Germinated barley foodstuff (GBF), which contains glutamine-rich protein and 
hemicellulose-rich fiber, has shown to prevent colitis activity - by reducing epithelial 
inflammatory responses - and body weight loss in an animal model of colitis. Administration of 
GBF augments SCFA production which increases cecal butyrate levels, improving colonic 
epithelial cell proliferation (Kanauchi et al., 2003). Furthermore, the flavonoid Bacalein, 
isolated from the roots of Scutellaria baicalensis Georgi (Labiatae), reduced and ameliorated 
the inflammatory symptoms of the dextran sulfate sodium (DSS)-induced colitis. Its effect was 
reported to be similar to that of sulfasalazine, the reference drug used for the treatment of 
ulcerative colitis in humans (Hong et al., 2002a). Also the phytochemical tryptanthrin, isolated 
from the indigo plant Polygonum tinctorium, may have therapeutic effect on colitis (Micallef et 
al., 2002).  
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OBJECTIVES 
 
The present thesis was undertaken to identify natural anti-inflammatory compounds 
with the ability to prevent and/or treat intestinal inflammatory diseases, including IBD. 
However, the purpose of this work was not to search for a new substance with similar but 
lower side effects to the commercial drugs already “in use” to treat such disorders. This project 
focused more on the effects of natural compounds and whole plant extracts in reducing 
inflammatory features by regulating, for example, unbalanced cytokines/chemokines produced 
in response to an antigen or pathogen. Such a compound or even the whole plant extract 
could improve life-style by affecting inflammation in the beginning of the “inflammatory” 
cascade, reducing the acute phase and preventing or delaying the relapse of the disease. 
Furthermore, natural substances could be use in IBD where the usage (application rate and 
frequency) of highly efficient anti-inflammatory drugs could be reduced. 
Specific goals were defined as follows: 
• Development and characterization of an appropriate human in vitro cell culture model 
that is closely related to the human intestinal epithelium, where GI inflammation can be 
mimicked. 
• Characterization of the anti-inflammatory properties of isoflavones and polyphenols on 
mediators involved in GI inflammation. 
• Determination of the anti-inflammatory effects of natural extracts on GI function. 
• Identification of the cellular and molecular mode of action of related compounds in 
intestinal inflammatory responses through a comprehensive gene expression analysis. 
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MATERIAL AND METHODS 
 
Reagents 
Recombinant human TNF-α and IL-1β were purchased from Peprotech (London, UK). 
Recombinant human IL-8, purified mouse anti-human IL-8 and biotinylated mouse anti-human 
IL-8 were obtained from BD Pharmingen (San Diego, CA, USA). Recombinant human 
MIP-3α/CCL20, anti-human MIP-3α/CCL20 and biotinylated anti-human MIP-3α/CCL20 were 
purchased from R&D Systems (Wiesbaden-Nordenstadt, Germany). Cell culture reagents 
were obtained from GIBCO (Basel, Switzerland). EGCG (TeavigoTM), curcumin and resveratrol 
were obtained from DSM Nutritional Products (Basel, Switzerland). Extracts of BS and RO 
were obtained from Sabinsa Corporation (Piscataway, NJ, USA). IκBα C-21 (sc-371), 
NF-κB p65 (sc-109) were purchased from Santa Cruz Biotechnology (Labforce, Nunningen, 
Switzerland). Anti-actin (rabbit; A-2066) antibody was obtained from Sigma-Aldrich Chemie 
(Steinheim, Germany). Primers and probes were purchased from Sigma-Genosys (Homefield 
Road, Haverhill, UK). 
 
Cell culture 
HT29 and T84 cells were obtained from ATCC (LGC Promochem, Molsheim, France). HT29 
and T84 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 
50 units/mL penicillin, 50 μg/mL streptomycin, L-glutamine and nonessential amino acids 
(NEAA, Invitrogen, Basel, Switzerland). Cells were maintained in a water-saturated 
atmosphere of 95% O2 and 5% CO2 at 37°C. Cells were used between passages 20 to 50. For 
experiments, cells were seeded at 0.5x106 and 1x106 cells/well into 12-well-plates and at 
0.2X105 cells/well into 96-well-plates and used after 3 or 4 days of pre-culture. They were 
starved in DMEM containing 0.25% FBS for 18 hours before the experiments. Cells were 
stimulated with TNF-α (100 ng/mL) and/or IL-1β (5 ng/mL) in phenol-free DMEM containing 
0.25% FBS. EGCG, extracts of BS containing a minimum of 40% β-BAs, and of RO which 
contain 15% carnosic acid and 20% ursolic acid were dissolved in DMSO and added to the 
culture medium concomitantly with the stimulus. Where appropriate, DMSO was added to the 
cell culture at a final concentration of 0.5% (v/v). 
 
Cytotoxicity 
Released lactate dehydrogenase (LDH) was measured in culture supernatants immediately 
after harvesting, using LDH enzyme controls as standard (Sigma, St. Louis, USA). In a 
microtiter plate, 20 μL of undiluted culture supernatants or standard were mixed with β-NAD 
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solution (172 mM) and Tris acetate buffer (13.6 g/L Tris base, 12.8 g/L KCl, 5.08 g/L L-lactate, 
1 g/L NaN2, pH 9.3). The kinetics of the reaction was measured at 340 nm at 30°C for 5 min. 
To determine the total LDH contents, cells were lysed in the presence of a buffer containing 
0.1 M NaCl, 1 mM EDTA, 10 mM Tris/HCl and 1% Triton X-100, and protease inhibitors. This 
protocol was adapted from Korzeniewski and coworker (Korzeniewski and Callewaert, 1983).  
 
Enzyme-linked immunosorbent assay (ELISA) and Enzyme 
Immunoassay (EIA) 
PGE2 assay. The amount of PGE2 in culture supernatants was assayed with EIA kits (obtained 
from Cayman Chemicals, Ann Arbor, MI, USA) according to the manufacturer’s instructions.  
IL-8 assay. Nunc Maxisorp 96-well microtitre plate (Fisher Scientific, Wohlen, Switzerland) was 
coated with 3 μg/mL goat anti-human IL-8 antibody (Pharmingen, Becton Dickinson, 
Heidelberg, Germany) in 50 μL binding buffer (0.1 M Na2HPO4, pH 9.0) overnight at 4°C. After 
washing with PBS containing 0.05% Tween 20 (PBS-T), wells were blocked with PBS 
containing 10% FBS and incubated for two hours at room temperature. After further washing 
with PBS-T, 100 μL aliquots of culture supernatant or recombinant IL-8 were added and 
incubated overnight at 4°C. To detect bound IL-8, 0.25 μg/mL biotinylated anti-human IL-8 
antibody (Pharmingen, Becton Dickinson, Heidelberg, Germany), mixed in blocking buffer, 
was added for one hour at room temperature. Streptavidin and alkaline phosphatase (DAKO, 
Glostrup, Denmark), diluted 1:50 in PBS, were pre-incubated for 30 min at room temperature 
to form conjugates. These conjugates were then added to the plate and incubated at 37°C for 
1 hour. After washing, 50 μL of p-nitrophenyl phosphate substrate (1 mg/mL) (Sigma, 
Steinheim, Germany) was added to each well and incubated at 37°C for 20 min. The optical 
density at 405 nm was read using a microtitre plate photometer (Molecular Devices, USA). All 
determinations were performed in triplicates. 
MIP-3α assay. Nunc immunosorb microtitre plate (Fisher Scientific, Wohlen, Switzerland) was 
coated overnight at 4°C with 2 μg/mL goat anti-human MIP-3α / CCL20 antibody (R&D 
Systems, Wiesbaden–Nordenstadt, Germany) diluted in 50 μL of carbonate coating buffer 
(pH 9.6). After washing with PBS-T, wells were blocked with PBS, containing 1% BSA, 
5% sucrose and 0.05% NaN3, for one hour at room temperature. After further washing with 
PBS-T, 50 μL aliquots of culture supernatants or recombinant MIP-3α were added for two 
hours at room temperature. To detect bound MIP-3α, 0.5 μg/mL biotinylated anti-human 
MIP-3α antibody (R&D Systems, Wiesbaden – Nordenstadt, Germany), mixed in blocking 
buffer, was added and the plate was incubated for one hour at room temperature. 
Streptavidin-biotin alkaline phosphatase complexes (DAKO, Glostrup, Denmark) were formed 
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and immune complexes visualized and measured as described above. All determinations were 
performed in triplicates. 
 
Whole cell protein extracts  
RAW 264.7 cells were stimulated with or without LPS (1 μg/mL) for 20 min. Cells were harvest 
and lysed in NETT-C (0.1 M NaCl; 10 mM Tris/HCl, pH 7.6; 1 mM EDTA; 1% Triton X-100 
mixed with a cocktail of protease inhibitors (CompleteTM, Roche Diagnostics, Mannheim, 
Germany)). Lysates were kept on ice for 15 min, sonicated (Branson Sonifier, 30% duty cycle, 
output control 3-4), cleaned by centrifugation (14000 rpm for 2 min at 4°C) and stored at -80°C 
until use. Protein concentration of extracts was measured using bicinchoninic acid (BCA) 
reagents according to manufacturer’s instruction (Pierce, Rockford, IL, USA).  
 
Cytoplasmic and Nuclear protein extracts 
Cells were harvested after 10 and 20 min of incubation, kept on ice and washed twice with ice-
cold PBS. After scraping them off with 400 μL of ice-cold buffer A (10 mM HEPES, pH 7.9; 
10 mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM DTT; completed with protease inhibitors 
cocktail (CompleteTM)). Twenty five μL of 10% NP-40 (Fluka, Steinheim, Germany) were 
added to the cells, mixed by vortexing for 10 sec and centrifuged at 14000 rpm, 4°C for 15 
sec. Cytoplasmic proteins (supernatant) were collected in a new tube. The pellet was 
resuspended in 50 μL of ice-cold buffer C (20 mM HEPES, pH 7.9; 0.4 M NaCl; 0.1 mM EDTA; 
0.1 mM EGTA; 1 mM DTT; completed with protease inhibitors at a final volume of 10 mL), 
mixed and incubated for 15 min at 4°C. After centrifugation (14000 rpm, 4°C for 5 min), 
nuclear extract was obtained by transferring the supernatant to a new tube. Both cytoplasmic 
and nuclear extracts were frozen in liquid nitrogen and stored at -80°C. Protein concentration 
of extracts was measured as described above.  
 
Immunoblot 
Protein samples were mixed with one volume Tricine-SDS sample buffer (Invitrogen, 
Carlsbad, CA, USA) containing 10% of 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, 
USA) and heated at 95°C for 5 min. Ten to thirty μg of proteins were separated by 
electrophoresis in 10-20% of Tricine gels (Novex, San Diego, CA, USA) and transferred to a 
nitrocellulose membrane. Membranes were incubated for 2 hours in blocking reagent (BR; 
Roche Diagnostics, Mannheim, Germany). Antibodies against IκB-α, NF-κB p65 or actin were 
diluted with PBS-T (PBS, 0.05% Tween 20) / 0.2 x BR (final dilution 1:1000). After washing 
with PBS-T, membranes were incubated with antibodies for 2 hours or overnight. Appropriate 
secondary antibody conjugated to horseradish peroxydase (i.e. donkey anti-rabbit IgG) was 
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first diluted 1:10 000 in PBS-T and incubated with the membrane for 45 min. Immune 
complexes were visualized by enhanced chemiluminescence (ECL; Amersham, Piscataway, 
NJ, USA) using high performance chemiluminescence film (Amersham). 
 
Analysis of NF-κB DNA binding using Electrophoretic Mobility Shift 
Assay (EMSA) 
Oligonucleotide probe labeling. 1 μL double stranded oligonucleotide (25 ng/μL; 5’-AGT TGA 
GGG GAC TTT CCC AGG C-3’ and 3’-TCA ACT CCC CTG AAA GGG TCC G-5’; Promega, 
USA) was radioactively labeled using 5 μL 10x kinase buffer (provided with the kinase), 1 μL 
T4-polynucleotide kinase (New England Biolabs) and 37 μL sterile double distilled H2O. By 
using 5 μL [γ- 33P]-ATP (3000 Ci/mmol; Amersham, Freiburg, Germany) as a substrate, the 
radioactive γ-phosphate of [γ- 33P]-ATP is transferred to the 5’-OH in the DNA, generating a 5’-
[33P]-phosphate-labeled oligonucleotide. The mixture was incubated for 60-90 min at 37°C and 
purified by using MicroSpin G-25 columns (Amersham, Freiburg, Germany).  
EMSA. Ten to 20 μg of protein extracts (nuclear and cytoplasmic) were added to a reaction 
mixture containing 20 μg of bovine serum albumin (Sigma, Deisenhofen, Germany), 2 μg of 
poly-desoxyinosinyl-desoxycytidylic acid, double stranded (poly(dIdC); Roche Molecular 
Biochemicals, Mannheim, Germany), 2 μL of buffer D+ (20 mM Hepes, pH 7.9; 20% glycerol; 
100 mM KCl; 0.5 mM EDTA; 0.25% NP-40; 2 mM DTT; 0.1% phenylmethylsulfonyl fluoride), 4 
μL of Buffer F (20% Ficoll 400, 100 mM Hepes, 300 mM KCl, 10 mM DTT, 0.1% 
phenylmethylsulfonyl fluoride), and 100000 cpm (Cerenkov) of a [33P]-labeled oligonucleotide, 
made up to a final volume of 20 μL with distilled water. Samples were incubated at room 
temperature for 25 min. After the incubation, samples were loaded on a non-denaturating 4% 
polyacrylamide gel and electrophoresis was run at 200V (22 to 14 mA) for 90 min. The gel was 
transferred to a Whatman 3MM paper (Schleicher & Schüll, Kassel, Germany) and dried under 
vacuum. Subsequently, the gel was exposed to a Phosphoimager BAS film (Fujifilm) for 
24 hours. Detection was performed by a Phosphoimager (Fujifilm). 
 
RNA isolation and reverse transcription (RT) 
Total RNA was isolated using the RNeasy® Mini Kit from Qiagen (Hilden, Germany). 
Extraction was performed according to the manufacturer’s directions. Matrix-bound RNA was 
eluted with 30 μL of RNase-free water. The quantity and purity of RNA was determined by 
measuring the optical density at 260 nm and 280 nm. Subsequently, 1.5 to 3.5 μg of total RNA 
were converted to first strand cDNA using SuperScript IITM reverse transcriptase (Invitrogen, 
Basel, Switzerland) and 50 ng/μL random hexamers (Microsynth, Balgach, Switzerland). The 
  Material and Methods 
  34  
conditions for the cDNA synthesis were: 5 min at 70°C for random primer annealing followed 
by cooling on ice; 10 min at room temperature, 50 min at 42°C and 15 min at 70°C for the 
denaturation step; and 20 min at 37°C for the RNase H digestion. The cDNA was 
subsequently diluted to 100 μL in water and stored at –80°C. 
 
Quantitative Real Time RT-PCR analysis 
The analysis of mRNA expression profiles was performed with multiplex quantitative 
RT-polymerase chain reaction (PCR). In a 50 μL PCR reaction, 3 μL cDNA (corresponding to 
30-50 ng of total RNA input) were amplified in an ABI Prism 7700 Sequence Detector (PE 
Biosystems, Foster City, CA, USA), using 2x Taqman Universal PCR Master Mix (Applied 
Biosystems, Rotkreuz, Switzerland), 50 nM primers and 100 nM probe for the 18S rRNA 
reference gene, and 300 nM primers and 100 nM probe for genes of interest. The probe for 
18S rRNA was fluorescently labelled with VICTM on the 5’ end and TAMRA on the 3’ end 
(Applied Biosystems, Rotkreuz, Switzerland), whereas probes for the genes of interest were 
labelled with 6-carboxy-fluorescein (FAM) on the 5’ end and TAMRA on the 3’ end. The PCR 
amplification conditions consisted of 2 min at 50°C and 10 min at 95°C, followed by 40 cycles 
of 15 and 60 sec at 95°C and 60°C, respectively. For gene sequences see Table 2. 
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Table 2. Gene sequences used in quantitative RT-PCR. 
 
Gene 
Forward and reverse primers 
(5’→ 3’) 
Probe 
(5’ → 3’) 
18S rRNA 
CGGCTACCACATCCAAGG 
CGGGTCGGGAGTGGGT 
 
TTGCGCGCCTGCTGCCT 
 
IL-8 
ACTGACATCTAAGTTCTTTAGCACTCC 
GCCTTCCTGATTTCTGCAGC 
 
TGGCAAAACTGCACCTTCACACAG 
 
TNF-α TCGAACCCCGACTGACAA AGCTGCCCCTCAGCTTG 
 
CCTGTAGCCCATGTTGTAGCAAACCC 
 
COX-2 
GCCCTTCCTCCTGTGCC 
AATCAGGAAGCTGCTTTTTACCTTT 
 
ATGATTGCCCGACTCCCTTGGGTGT 
 
MIP-2 
AGTCCCCCGGACCCC 
GCCCATTCTTGAGTGTGGC 
 
CTGCGCCCAAACCGAAGTCAT 
 
MIP-3α TGTCAGTGCTGCTACTCCACCT CCAAGACAGCAGTCAAAGTTGC 
 
TGCGGCGAATCAGAAGCAGCA 
 
GRO-α AAGTCCCCCGGACCCC TTCCGCCCATTCTTGAGTGT 
 
CTGCGCCCAAACCGAAGTCATAGC 
 
GRO-γ GTCCCCCGGACCCCA ACAAGCTTTCTTCCCATTCTTGAG 
 
CGCCCAAACCGAAGTCATAGCCAC 
 
IL-1α CTGGAGGCCATCGCCA TGCTCAGGAAGCTAAAAGGTGC TGACTCAGAGGAAGAAATCATCAAGCCTAGGTC 
IL-1β GGCCTCAAGGAAAAGAATCTGTAC GGGATCTACACTCTCCAGCTGTAGA TCCTGCGTGTTGAAAGATGATAAGCCCA 
PGES 
TGTACGTGGTGGCCATCATC 
CTCAGGGCATCCTCGGG AGGCTGCGGAAGAAGGCCTTTGC 
MMP-14 
CTGCCGAGCCTTGGACTG 
CGTGCACAGCCACCAGG 
 
CAGGAATGAGGATCTGAATGGAAATGACATCT 
 
5-LOX 
CGGCGATGTCGAGGTTG 
TGTGAATTTGGTCATCTCGGG 
 
TGAGGGATGGACGCGCAAAGTTG 
 
RANK 
GCTTGCTGCATAAAGTTTGTGA 
TGTTGCCGGCGACCA AGGCAAGGCCCTGGTGGCC 
IEX-1L 
TCTCTACCCTCGAGTGGTGAGTATC 
ACTCCAGGGCAGCGCA CCGAAGTGGGCATTCGCGGT 
β-integrin 5 CCCAAAATGTGCCTGGTG CCGAGAGGTGATGGACCG TCCAAAGAGGACTTCGGAAGCCC 
IP-10 
TGAAATTATTCCTGCAAGCCAA 
CAGACATCTCTTCTCACCCTTCTTT GTCCACGTGTTGAGATCATTGCTACAATG 
RANTES 
ACCAGTGGCAAGTGCTCCA 
GCACACACTTGGCGGTTCTT CCCAGCAGTCGTCTTTGTCACCCG 
FRA-1 
CACGACCCATCTGCAAAA 
GCCACTGGTACTGCCTGTGTC CCCGGAAGGAGCCAAGGAGGG 
CFb 
TGCTGACCCCAATACTTGCA 
GAATGAAACGACTTCTCTTGTGAACT AGGTGATTCTGGCGGCCCCTTG 
 
Primers and probes sets were designed with the Primer ExpressTM software (Applied Biosystems, Rotkreuz, 
Switzerland). 
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mRNA abundance was defined using the ΔCT method according to the manufacturer's protocol 
(ABI Prism 7700 Sequence Detection System, Rotkreuz, Switzerland). Briefly, the ΔCT for the 
gene of interest was determined as the difference between the CT values for the gene of 
interest and 18S rRNA, where the CT value is the cycle threshold. The standard deviation (SD) 
was obtained from ΔCT of cDNA samples assayed in duplicate, where the upper and lower 
errors were defined as 2-(ΔCT-SD) and 2-(ΔCT+SD), respectively. ΔΔCT was determined as the 
difference in ΔCT of unstimulated cells compared to that of each treatment group. The mRNA 
level for the gene of interest was determined as 2-ΔΔCT and, therefore, reflects changes relative 
to unstimulated cells. Each cDNA sample was assessed in duplicates.  
 
Affymetrix GeneChip® hybridization 
GeneChip® hybridization was carried out as described previously (Siler et al., 2004). Briefly, 
RNA (10 μg) was subjected to double-stranded (ds)-cDNA synthesis with T7-d(T)24 primers 
and the Superscript™ II choice system (Invitrogen), followed by an in vitro transcription 
reaction (T7 MegaScript kit, Ambion, Austin, TX) to generate the hybridization probes. The 
cRNA was labeled by incorporation of biotin-11-CTP and biotin-16-UTP (Roche Molecular 
Systems, Penzberg, Germany). cRNA (10 μg) was fragmented by incubation in 40 mM Tris-
acetate, pH 8.1; 100 mM KOAc; and 30 mM MgOAc for 35 min at 95°C. Samples were 
hybridized to the human genome U133A array (Affynetrix, Santa Clara, CA) for the screening 
of transcripts as described in the Gene Chip Expression Analysis Technical Manual 
(Affymetrix, Oxford, UK). Each treatment was done in quadruplicates and was represented by 
four chips. Fragmented cRNA was hybridized overnight with 1x MES and 0.01% Tween-20 at 
45°C. The arrays were washed at a maximal stringency of 1x MES and 0.01% Tween-20 at 
50°C (Fluidics program EukGE-WS2). Hybridization signals were detected by streptavidin-
phycoerythrine staining (Molecular Probes, Leiden, Netherlands), which was amplified by 
incubation with anti-streptavidin antibody (Vector Labs, Orton Southgate, Great Britain) and 
staining with streptavidin-phycoerythrine. Subsequently, the microarrays were subjected to 
laser scanning (GeneChip® Scanner 3000; Affymetrix, Bedford, MA, USA), and the 
hybridization signals were analyzed with the GeneChip Analysis Suite MAS 5.0 (Affymetrix). 
 
GeneChip® data analysis 
The gene chip data analysis was carried out using RACE-A (Roche Affymetrix Chip 
Experiment-Analysis), a Roche proprietary software package for differential expression 
analysis as described (Siler et al., 2004). Briefly, the workflow supported by RACE-A 
comprises the following steps: (1) selection and quality assessment of probe arrays; (2) 
reading probe set intensities reported by Affimetrix chip analysis software; (3) assignment of 
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chip replicates to experimental conditions; (4) comparisons of experimental conditions; (5) 
filtering of comparison results based on a variety of attributes calculated by RACE-A; and (6) 
output to Excel® table format. 
During step (3), probe arrays were normalized against the mean signal intensity of each chip 
and outlier genes were removed. Gene expression in each treatment was compared with that 
of unstimulated cells. Treatment-induced changes in gene expression levels are reported as 
“change factor” relative to unstimulated cells. Change factors > 0.5 represent an up-regulation 
by EGCG compared to control, and < 0.5 indicate a down-regulation. Changes were 
considered significant, if either the P value was < 0.01 for a single gene regulated by EGCG, 
or if a group of genes involved in a certain pathway or biological process was consistently 
regulated in the same direction.  
 
Statistical analysis 
The upper and lower limits of mRNA expression levels were calculated as described above. 
All other values are presented as mean ± SD and all statistics were evaluated double-sided 
using a two-sample equal variance Student’s t-test, assuming independent variance. 
* p < 0.05, ** p < 0.01 and *** p < 0.001 were considered to be significant. For the microarray 
analysis, only genes with p < 0.01 were used. 
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ABSTRACT 
 
A major component in green tea, epigallocatechin-3-gallate (EGCG), is reported to interfere 
with different steps of a number of inflammatory pathways. After oral administration, EGCG is 
retained in the gastro-intestinal tract, where it is thought to exert preventive functions against 
inflammatory bowel disease (IBD) and colon cancer. In this study, the human colon 
adenocarcinoma cell lines HT29 and T84 were used to investigate the effect of EGCG on 
intestinal inflammation. HT29 and T84 cells were stimulated with tumor necrosis factor 
(TNF)-α to induce the “inflammatory” condition and to trigger the inflammatory cascade in 
vitro, and treated with EGCG to study its effect on inflammatory processes. The secretion of 
the chemokines interleukin (IL)-8 and macrophage inflammatory protein (MIP)-3α and 
prostaglandin E2 (PGE2) was determined by ELISA. The gene expression level was measured 
by quantitative real-time (RT)-PCR. Treatment of TNF-α-stimulated HT29 cells with EGCG 
dose-dependently inhibited the synthesis of IL-8, MIP-3α and PGE2. Treatment with EGCG 
also inhibited the production of IL-8 and MIP-3α in TNF-α-stimulated T84 cells. Gene 
expression analysis in both HT29 and T84 cells revealed that EGCG down-regulates genes 
involved in inflammatory pathways. This study shows that EGCG acts at different levels on the 
production of chemokines and PGE2 in the chemokine and eicosanoid-pathways of colon 
epithelial cells. Therefore, EGCG might prove useful for the prevention and/or attenuation of 
colonic disorders. 
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INTRODUCTION 
 
The constant exposure of the intestinal epithelium to diverse types of nutrients and 
microorganisms present in the natural flora leads to a permanent “stress state” for the 
enterocytes. Mucosal surfaces of the intestinal tract form one of the main routes for microbial 
pathogens to enter a host, and are important sites of microbially-induced diseases. In some 
food allergies or after invasion of the epithelium by pathogenic bacteria, the intestinal mucosa 
is irritated. This might lead to acute inflammation, characterized by an excessive production of 
inflammatory mediators. These are, in part, responsible for the recruitment of specific cell 
types, for example, macrophages/monocytes, lymphocytes or neutrophils (Kagnoff, 1996). 
During intestinal inflammation, polymorphonuclear leukocytes (PML), including 
neutrophils, migrate into the mucosa. In the intestine, an exacerbation of destructive 
processes occurs due to different pro-inflammatory and chemoattractant molecules. The latter 
are chemokines, a large family of small proteins, which are involved in innate immune and 
inflammatory responses by chemoattracting to, and activating leukocytes at the site of 
inflammation, and up-regulating adhesion molecules important for leukocyte trafficking 
(Baggiolini and Moser, 1997; Dwinell et al., 1999). Biological actions of chemokines are 
mediated through G-protein-coupled receptors which are present on the surface of target cells 
(Balkwill, 1998; Murphy et al., 2000). These receptors exhibit overlapping specificity for 
chemokines within each subfamily, and the cellular expression of respective receptors 
determines which cell types respond to a given chemokine. Based on the arrangement of their 
N-terminal cysteine residues, chemokines are subdivided into four subfamilies, including CXC 
and CC. Cells responsive to chemokines recognize concentration gradients and migrate 
towards the source of chemokine secretion. IL-8, MIP-2 and growth-regulated oncogene 
(GRO)-α and GRO-γ are CXC chemokines which attract and activate neutrophils, whereas the 
CC chemokines, such as MIP-3α, activate leukocyte populations, including monocytes, 
T lymphocytes, DC and, to a lesser extent, neutrophils (Ajuebor and Swain, 2002). 
Chemokines contribute to the perpetuation of inflammatory processes, increasing chronic 
intestinal inflammation and mucosal destruction. Secreted chemokines and their specific 
chemokine cell-surface receptors play a crucial role in the final composition of leukocytes 
present in the inflamed intestine (MacDermott, 1999; Banks et al., 2003). 
Prostaglandins are also involved in the regulation of a variety of physiological and 
pathological processes in the immune response and in inflammation. Prostaglandin E2 (PGE2) 
and other prostanoids are generated through two bifunctional enzymes, cyclooxygenases-1 
and -2 (COX-1 and COX-2) (Kim et al., 1998). In general, COX-1 is constitutively expressed in 
a wide range of tissues including the gastro-intestinal tract and plays a role in the tissue 
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homeostasis, e.g. maintenance of gastro-intestinal integrity (Singer et al., 1998). The inducible 
form, COX-2, which regulates prostaglandin synthesis, is overexpressed in several epithelial 
cancers and at sites of inflammation (Parker et al., 1997; Kim et al., 1998; Singer et al., 1998; 
Poligone and Baldwin, 2001; Martel-Pelletier et al., 2003). The expression of this enzyme is 
induced by various stimuli, e.g. TNF-α, IL-1β and phorbol esters, in a variety of cell lines. 
Natural compounds, such as components of green tea, influence inflammation and 
cancer (Chen et al., 2003). EGCG, the major catechin of green tea, has many biological 
functions, including anti-inflammatory and chemopreventive effects (Lin and Lin, 1997; Ahn et 
al., 2004; Park and Surh, 2004). In China, Korea and Japan, where a large proportion of the 
population consumes green tea daily, the incidence of colon cancer is relatively low compared 
with that found in Western societies. EGCG interferes in several steps of inflammatory 
processes, e.g. in the synthesis of eicosanoids, and in the chemokine-mediated recruitment of 
PML to the injured site (Chen et al., 2002). Furthermore, EGCG was shown to suppress the 
maturation of murine DC through the inhibition of ERK, p38 kinase, JNK and the NF-κB 
signaling pathway (Ahn et al., 2004). In vivo studies show that green tea polyphenols 
decrease inflammation in animal models (Varilek et al., 2001). 
Several reports have shown the benefits of EGCG in a variety of inflammatory 
conditions. In the present study, we evaluate the anti-inflammatory effects of EGCG in vitro. 
Human colon adenocarcinoma cell lines HT29 and T84 were stimulated with TNF-α and the 
potential of EGCG to improve gastro-intestinal inflammation, by modulating expression of 
cytokines and chemokines, was studied. Here we show that EGCG effectively modulates a 
number of mediators involved in different inflammatory diseases on protein and gene 
expression level. Our results suggest that EGCG may be of preventive and, furthermore, 
therapeutic value to treat intestinal inflammation. 
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RESULTS 
Impact of EGCG on the viability of intestinal epithelial cells 
The cytotoxicity of cell treatments and EGCG was evaluated by measuring the LDH 
activity in cell culture supernatants. Table 3 shows percentages of LDH released in HT29 and 
T84 cells. For HT29, the amount of released LDH was similar in the different treatments, 
indicating that TNF-α and EGCG did not affect the cell viability to a higher extent than TNF-α. 
This, however, might induce apoptosis. T84 cells treated with 25 μM of EGCG displayed 
higher LDH release than untreated cells, suggesting that EGCG might induce apoptosis. 
 
Table 3. Determination of cell viability in HT29 and T84 cells treated with EGCG. 
 
Cell viability  
HT29 
(% of LDH contents) 
T84 
(% of LDH contents) 
Unstimulated cells 2.5 ± 0.0 1.3 ± 0.1 
TNF-α (100 ng/ml) 5.8 ± 1.7 2.4 ± 0.4 
EGCG (50 μM) 5.1 ± 1.3 0.6 ± 0.2 * 
EGCG (25 μM) 2.3 ± 1.0 2.5 ± 0.7 
TNF-α +  EGCG (50 μM) 4.6 ± 0.4 1.9 ± 0.0 
TNF-α + EGCG (25 μM) 6.3 ± 0.4 6.2 ± 0.7 * 
 
Cells were stimulated with 100 ng/ml of TNF-α and incubated in presence or absence of varying concentrations of 
EGCG. After 24 hours, LDH was determined in culture supernatants immediately after harvest. Results are given 
as percentage of total LDH contents ± SD. Similar data have been obtained in at least two independent sets of 
experiments.  
 
TNF-α induces the secretion of chemokines 
TNF-α is an important pro-inflammatory mediator involved in gastro-intestinal 
inflammation and able to activate the synthesis of chemokines in epithelial cells (MacDermott, 
1999). Therefore, we verified its effects on the production of IL-8 and MIP-3α in HT29 and 
T84 cell lines. Cells were cultured in the presence or absence of TNF-α for 24 hours and the 
secretion of these chemokines was examined. Unstimulated cells did not produce significant 
levels of IL-8 and MIP-3α. In contrast, TNF-α-activated cells demonstrated time- and 
dose-dependent synthesis of IL-8 and MIP-3α in HT29 (Fig. 4A and C). Similar data for the 
dose-dependent secretion of both chemokines were also obtained in T84 cells (data not 
shown). The time-dependent production of IL-8 and MIP-3α in TNF-α-stimulated T84 cells is 
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shown in Figure 4B and D. Compared to T84 cells, the production of IL-8 in activated 
HT29 cells was 1.5 fold increased after 24 hours. However, no significant differences were 
observed on the MIP-3α production between both cell lines (Fig. 4). 
 
Figure 4: Induction of IL-8 and MIP-3α production by TNF-α-stimulated HT29 and T84 cells 
Unstimulated and TNF-α-stimulated HT29 and T84 cells were cultured for 4 to 24 hours. IL-8 and MIP-3α secretion 
were measured in culture supernatants by ELISA. Representative data of one of three similar experiments are 
given. A and B, dose- and time-dependent increase of IL-8 production in HT29 and T84 cells, respectively. C and 
D, dose- and time-dependent increase of MIP-3α secretion in HT29 and T84 cells, respectively. 
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EGCG inhibits the production of IL-8 and MIP-3α in intestinal epithelial cells 
The effects of EGCG on the IL-8 and MIP-3α secretion were investigated after 24 and 
72 hours in TNF-α-stimulated HT29 and T84 cells. EGCG significantly reduced the production 
of IL-8 at 24 hours (Fig. 5A) and virtually abolished it at 72 hours (Fig. 5B). Increasing 
concentrations of EGCG gradually reduced IL-8 secretion in activated cells, indicating that the 
secretion of IL-8 from the cell to the culture medium was more affected in the presence of 
EGCG in HT29 than in T84 cells (Fig. 5C). This indicates a difference in the sensitivity of these 
cells to EGCG.  
 
 
Figure 5: EGCG inhibited the production of IL-8 in epithelial cells 
Levels of IL-8 in supernatants of unstimulated and TNF-α-stimulated HT29 and T84 cells cultured for 24 (A) and 
72 (B) hours in the presence of 50 μM of EGCG. EGCG dose-dependently inhibited the synthesis of IL-8 in these 
epithelial cells (C). TNF-α-activated HT29 and T84 cells produced 21704 pg/ml and 20962 pg/ml IL-8, respectively. 
The secretion of IL-8 was determined by ELISA. * p < 0.05, ** p < 0.01. Representative data of one of three similar 
experiments are shown.  
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To investigate the impact of EGCG on MIP-3α secretion, TNF-α-activated cells were 
incubated with varying concentrations of EGCG for 24 hours. EGCG dose-dependently 
decreased the synthesis of MIP-3α in both cell lines (Fig. 6A). The production of MIP-3α was 
also investigated after 72 hours of culture (Fig. 6B). As expected, TNF-α strongly increased 
the synthesis of MIP-3α in both HT29 and T84 cells. This increase was significantly reduced in 
the presence of EGCG at a concentration of 50 μM.  
 
Figure 6: Effect of EGCG on TNF-α-induced MIP-3α production in HT29 and T84 cells 
Cells were stimulated with 100 ng/ml of TNF-α in the presence of varying concentrations of EGCG for 24 hours (A). 
Unstimulated and stimulated cells were cultured for 72 hours in the presence of 50 μM of EGCG (B). The synthesis 
of MIP-3α was determined by ELISA. * p < 0.05, ** p < 0.01 and *** p < 0.001. Representative data of one of three 
similar experiments are shown. 
 
EGCG inhibits the production of PGE2 in epithelial cells 
Since it is known that intestinal epithelial cells produce PGE2 (Eckmann et al., 1997), 
we decided to investigated the influence of EGCG on its synthesis in activated HT29 cells. 
Unstimulated cells produced low amounts of PGE2. Upon TNF-α stimulation a significant 
increase on the PGE2 secretion was observed. Figure 7A shows that TNF-α dose-dependently 
augmented the secretion of PGE2 after 24 hours. The highest amount of PGE2 was obtained in 
cells stimulated in the presence of 100 ng/ml of TNF-α. In cells treated with 50 μM EGCG, 
PGE2 synthesis was diminished by 80 ± 6% (data not shown). EGCG dose-dependently 
reduced the production of PGE2 (Fig. 7B). 
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Figure 7: EGCG inhibited the secretion of PGE2 in TNF-α-activated HT29 cells 
HT29 cells were cultured with different concentrations of TNF-α for 24 hours (A). Stimulated cells were incubated 
with varying concentrations of EGCG for 24 hours (B). Activated cells produced 420 pg/ml of PGE2. The production 
of PGE2 was determined by ELISA. ** p < 0.01 and *** p < 0.001. Similar results were obtained in two other series 
of experiments.  
 
EGCG modulates genes involved in inflammatory responses 
In order to clarify whether EGCG modulates the expression of TNF-α-induced genes, 
we used quantitative RT-PCR. Since activated HT29 and T84 cells up-regulated inflammatory 
genes within 2-24 hours (Fig. 8), the influence of EGCG on these genes was analyzed after 
6 hours of culture. Basal gene expression levels in unstimulated HT29 cells were different, 
with weakly (e.g. TNF-α, MIP-2, GRO-α, IL-1α, IL-1β, IP-10), moderately (IL-8, MIP-3α, 
GRO-γ, PGES, MMP-14, RANK, IEX-1L, CFb) and abundantly (e.g. COX-2, 5-LOX, 
β 5 integrin, RANTES, FRA-1) expressed genes (Fig. 9). In T84 cells, however, basal gene 
expression levels differed from those of HT29 cells with respect to moderately (e.g. IL-8, 
MIP-3α, GRO-γ, PGES, MMP-14, RANK, IEX-1L, RANTES, CFb) and abundantly (e.g. 
COX-2, 5-LOX, β 5 integrin, FRA-1) expressed genes (data not shown). 
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Figure 8: Time-dependent up-regulation of specific genes in HT29 cells 
Cells were cultured without or with 100 ng/ml of TNF-α for 6 hours. RNA was isolated and gene expression levels 
of IL-8, TNF-α, MIP-3α and COX-2 were measured using the quantitative RT-PCR. Values are expressed relative 
to unstimulated cells at arbitrary units ± SD. Similar results were obtained in two other series of experiments. 
 
TNF-α induced a substantial increase in mRNA levels of cytokines and chemokines 
(TNF-α, IL-8, MIP-2, MIP-3α, GRO-α, GRO-γ, IP-10), in addition to COX-2. However, mRNA 
levels of other genes, including 5-LOX, RANK, and β 5 integrin, were unaltered by TNF-α 
stimulation. EGCG (50 μM) reduced the mRNA levels of IL-8, TNF-α, MIP-3α, MIP-2, GRO-α, 
GRO-γ and COX-2 by 40 to 85% in both cell lines (Fig. 10). This effect was specific, but not 
restricted, to these genes. Conversely, EGCG did not augment the expression of 
TNF-α-induced genes. TNF-α strongly augmented the expression of IL-8 mRNA levels in 
HT29 and T84 cells, while it moderately and weakly increased the expression of TNF-α, 
MIP-3α, and GRO-γ mRNA (Fig. 10A, B and E), COX-2 and GRO-α mRNA (Fig. 10C and D), 
respectively. Notably, these genes were significantly down-regulated by EGCG, an 
observation which is consistent with our results of produced chemokines (IL-8 and MIP-3α) 
(Fig. 5 and 6). 
Finally, the dose-dependent impact of EGCG on gene expression was evaluated. In 
HT29 and T84 cells, EGCG down-regulated IL-8, TNF-α, MIP-3α and COX-2 mRNA levels in 
the concentration range of 6.25 to 50 μM (Fig. 11). In T84 cells, EGCG at 12.5 and 25 μM did 
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not have any significant effect on IL-8 mRNA levels, although a trend for down-regulation was 
observed (Fig. 11B). In summary, expression levels of tested chemokines were significantly 
diminished following EGCG treatment in these cell lines. 
Figure 9: Expression levels of selected genes in HT29 cells 
RNA of unstimulated and TNF-α-activated HT29 cells which were cultured for 6 hours were isolated and the levels 
of mRNA of the indicated genes determined by quantitative RT-PCR. Values are expressed relative to 18S rRNA 
and are indicated as means ± SD of 2 to 4 experiments. 
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Figure 10: EGCG modulated the expression level of inflammatory genes 
Activated HT29 and T84 cells were cultured in the presence of 50 μM of EGCG for 6 hours. The effects of EGCG 
on mRNA expression levels of IL-8, TNF-α and MIP-3α in HT29 and T84 cells, respectively, were analyzed (A and 
B). The influence of EGCG on COX-2, GRO-α and GRO-γ mRNA levels in HT29 and T84 cells, respectively, are 
given (C, D and E). * p < 0.05, ** p < 0.01 and *** p < 0.001. Representative data of one of four similar experiments 
are shown.  
Chapter 1                              EGCG inhibits chemokine production and inflammatory mediators 
 
  50  
 
Figure 11: EGCG dose-dependently down-regulated some inflammatory genes 
TNF-α-stimulated HT29 (A) and T84 cells (B and C) were cultured in the presence of varying concentrations of 
EGCG for 6 hours. The effect of EGCG on the mRNA level of IL-8, TNF-α, MIP-3α and COX-2 is given. * p < 0.05, 
** p < 0.01 and *** p < 0.001. Representative data of one of three similar experiments ± SD are shown.  
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DISCUSSION 
 
In this report, we present evidence that EGCG beneficially affects the inflammatory 
response in the colon adenocarcinoma cell lines HT29 and T84. These cell lines were used as 
models for intestinal mucosal diseases and have different origins and phenotypes. In vitro, 
differentiated HT29 cells express characteristic features of mature intestinal cells, such as 
microvilli, small intestinal digestive enzymes, lipid droplets, primary and secondary lysosomes 
(Velcich et al., 1995). T84 is a transplantable human carcinoma cell line derived from a lung 
metastasis of colon carcinoma (Murakami and Masui, 1980) which possess secretory capacity 
such as small intestinal crypt cells.  
Our experimental approach dealt with the identification of the anti-inflammatory function 
of EGCG in TNF-α-activated colon adenocarcinoma cell lines. The effects of EGCG were 
determined at two levels: the expression of genes involved in inflammation and the production 
of chemokines (IL-8 and MIP-3α) and PGE2. EGCG showed potent effects on genes of the 
inflammatory pathway, including those of the cytokine/chemokine network (e.g. IL-8, TNF-α, 
MIP-3α, MIP-2, GRO-α and GRO-γ). CXC chemokines, such as IL-8, MIP-2, GRO-α and 
GRO-γ, are responsible for chemoattraction of neutrophils, while CC chemokines (e.g. 
MIP-3α) play a role in the recruitment of lymphocytes and DC to the inflamed tissue. Cytokines 
and chemokines are induced by TNF-α stimulation and are abundantly expressed and 
secreted in IBD (Fiocchi, 1997b; Fiocchi, 1997a; Ajuebor and Swain, 2002; Banks et al., 2003; 
Kaser et al., 2004; Papadakis, 2004). We demonstrated that EGCG markedly diminished the 
expression and secretion of IL-8 and MIP-3α in colon epithelial cells.  
IBD and colon cancer are associated with an increased activity of intestinal immune 
cells, which augments the production of pro-inflammatory cytokines, including TNF-α. 
Therefore, TNF-α was used to induce an inflammatory state in vitro. TNF-α is involved in the 
mediation of the sustained inflammatory response and high amounts of this cytokine can be 
found in IBD patients (Dionne et al., 1998; D'Haens, 2003). The expression and production of 
IL-8 were studied in macrophages isolated from normal and inflamed colonic tissue resected 
for IBD (Grimm et al., 1996). Macrophages from IBD expressed more IL-8 mRNA than those 
from the normal mucosa, and lipopolysaccharide treatment further increased it. In addition, the 
recruitment of macrophages may be responsible for the IL-8 secretion which leads to 
neutrophil attraction in IBD (Grimm et al., 1996). This suggests that in the intestine activated 
macrophages migrate into the epithelium and secrete IL-8 which recruits PML to the injured 
site. This is supported by our macrophage in vitro model (data not shown) where 
RAW 264.7 cells were stimulated with LPS in the presence or absence of EGCG. In this study, 
we have identified EGCG as an inhibitor of IL-8. Moreover, after TNF-α stimulation, epithelial 
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cells also produce IL-8, and consequently, recruit PML. The inhibition of the expression and 
production of IL-8, either by EGCG or other natural compounds (i.e. phenolic compounds), 
interferes with the recruitment of PML and, thus, impedes progression and aggravation of 
inflammation (Sugimoto et al., 2002; Park and Surh, 2004). In conclusion, EGCG has the 
potential to reduce the IL-8 production in both epithelial cells and macrophages (Fig. 12).  
 
Figure 12: Crosstalk between epithelial cells (EC) and macrophages (M) in intestinal inflammation 
Macrophages migrate into the epithelium and secrete IL-8. Activated epithelial cells also produce IL-8. These 
enhance on IL-8 is responsible to chemoattract PML from the circulation, increasing the inflammatory response. 
EGCG inhibit the synthesis of IL-8, and therefore, the recruitment of PML, reducing inflammation. 
 
With regard to MIP-3α, it is synthesized by the human colon epithelial cells and 
therefore by HT29 cells which also express CCR6, the cognate receptor for MIP-3α 
(Izadpanah et al., 2001). MIP-3α mRNA and protein levels were found to be increased in 
colonic tissues from patients with IBD (Kwon et al., 2002). In the present study, EGCG 
inhibited the synthesis of MIP-3α in colon cancer cell lines and also down-regulated gene 
expression. Via MIP-3α production, intestinal epithelial cells recruit DC and memory T cells to 
the site of inflammation. Whereas the normal intestinal mucosa is home of dendritic and 
T cells, a specific T cell population immigrates during IBD and contributes to the generation of 
inflammation (Fiocchi, 1998). Therefore, an excess of these cells in the inflamed intestine 
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should be avoided. By reducing MIP-3α production, EGCG could prevent homing of these 
cells and consequently IBD symptoms.  
Furthermore, we observed that EGCG inhibits PGE2 production. In the gastro-intestinal 
environment, prostaglandins are important regulators of gastro-intestinal fluid secretion. In 
food allergies or after invasion of microorganisms, water secretion and TNF-α-induced 
electrolyte production lead to an increase of Ca2+-dependent PGE2 in the intestinal epithelium. 
Exogenous PGE2 up-regulated IL-8 gene expression and protein production in human colonic 
epithelial cells (Yu and Chadee, 1998). PGE2 production was increased in colonic fibroblasts 
and in IBD patients. Intestinal fibroblasts, beside epithelial cells, could be targets for PGE2 and 
sites of colonic prostanoid biosynthesis in vivo (Kim et al., 1998). The expression of COX-2 
has also been observed after Salmonella infection in intestinal epithelial cells (Singer et al., 
1998), and COX-2 protein was reported to be expressed in three of eight colon cancer cell 
lines, including HT29 (Parker et al., 1997). Our results demonstrated that EGCG diminished 
pro-inflammatory PGE2 production and expression in HT29 cells. Studies have shown that 
EGCG targets COX-2 by inhibiting the PGE2 production and possibly reduces the risk of colon 
cancer and inflammation in humans (August et al., 1999; Hong et al., 2001; Park and Surh, 
2004). Due to differences between HT29 and T84 cells, TNF-α-stimulated T84 cells did not 
produce detectable amounts of PGE2 and COX-2 protein (data not shown). With regard to this 
observation, in HT29 cells, EGCG had shown an influence on the three parameters tested: 
COX-2 gene, COX-2 protein expression (data not shown) and PGE2 generation, whereas in 
T84 cells, only the COX-2 mRNA levels were affected by EGCG.  
Quantitative RT-PCR analysis identified several genes that were induced in 
TNF-α-stimulated HT29 and T84 cells, including IL-8, TNF-α, MIP-3α, MIP-2, GRO-α and 
GRO-γ. These genes were down-regulated by EGCG and have NF-κB regulatory binding 
sites. Consequently, they are regulated by the transcription factor NF-κB. Similar to the effects 
observed for IL-8, the expression levels of MIP-2, GRO-α and GRO-γ were also diminished by 
EGCG in both cell lines. These chemokines, like IL-8, act through the chemokine receptor 
CXCR2 (Murphy et al., 2000) and are also elevated after TNF-α stimulation (Fig. 10D and E). 
The concerted effect of EGCG on four chemokines binding to a common receptor indicates 
that this flavonoid impedes most or all biological activities that are mediated by CXCR2. 
Furthermore, 5-LOX, an enzyme expressed in differentiated HT29 cells (Cortese et al., 1995) 
and responsible for the synthesis of leukotrienes, was also expressed in HT29 and T84 cell 
lines, but no differences was observed between unstimulated and TNF-α-activated cells 
(Fig. 9). In our experiments, the expression of 5-LOX was not influenced by EGCG (data not 
shown). A possible explanation for this observation is that TNF-α is not able to induce 5-LOX. 
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Collectively, we provide evidence that EGCG attenuates the inflammatory response in 
the colon adenocarcinoma cell lines HT29 and T84 by inhibiting the production of chemokines 
and PGE2. However, this study only refers to the effect of EGCG in the in vitro gastro-intestinal 
inflammation and, thus, it should be followed by in vivo experiments to consolidate this 
statement. In addition, in vivo studies will also corroborate the use of EGCG in preventing and 
attenuating gastro-intestinal disorders. 
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ABSTRACT 
 
As shown in the preceding chapter, EGCG exibits anti-inflammatory activities in human colon 
cancer cells. The aim of this study was to monitor the effects of EGCG on global gene 
expression in activated HT29 cells and to infer on its presumably wide effect on cellular 
physiology. Cells were stimulated with or without TNF-α (100 ng/mL) in the presence or 
absence of various concentrations of EGCG, and gene expression changes were determined 
after 6 hours of culture. TNF-α significantly influenced 700 of 14500 genes tested. These were 
sorted by their change factors and only those > 0.5 (up-regulated) and < -0.5 (down-regulated) 
were analysed (P value < 0.01). The gene chip analysis began with 179 genes where 151 
were up-regulated and 28 down-regulated by TNF-α; however, only 78 were described in this 
paper. Analyses revealed that EGCG alone mildly but significantly modulated the expression 
of genes involved in immune responses and inflammation, confirming previous results. In 
addition, genes involved in apoptosis, in growth factor signalling, and in transcription were also 
regulated by EGCG. TNF-α-stimulated cells markedly up-regulated chemokines, apoptotic 
signals, and cell adhesion molecules including ICAM-1. “Inflamed” cells exposed to EGCG 
reversed inflammatory responses induced by TNF-α, increasing survival signals and 
decreasing the production of chemokines and apoptotic signals. Interestingly, not all 
chemokines were altered by EGCG (e.g. granulocyte chemotactic protein - GCP-2). 
Furthermore, components of the extracellular matrix (ECM) including matrix metalloproteinase 
(MMP)-7, collagen and laminin 5 were up-regulated by EGCG, suggesting that EGCG might 
induce tissue remodelling and assist in the regeneration of the epithelium. Moreover, several 
components of specific signalling pathways such as NF-κB, AP1, MAPK and PI3K were 
affected by EGCG. This study has confirmed previous observations concerning the effects of 
EGCG on chemokines and extended knowledge on pathways or other processes affected by 
EGCG, including TNF/TNFR1 and growth factor signalling in addition to cell adhesion and cell 
death (caspase cascade). Furthermore, potential new leads to genes affected by EGCG that 
could play a role in the prevention of intestinal inflammation were identified such as those 
involved in barrier integrity. 
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INTRODUCTION 
 
As shown in the Chapter 1, EGCG acts as an anti-inflammatory agent in intestinal 
inflammation in vitro; however, the mode by which EGCG exerts its action is not completely 
elucidated. New techniques for the large-scale analysis of gene expression in host cells have 
opened an array of opportunities for studying cellular responses. In particular, global gene 
expression profiling using microarrays offers new opportunities to study and identify the effects 
of food components on the transcriptional level. By using cDNA microarrays the expression of 
thousand of genes can be studied in one experiment, in addition, leads to pathwas can be 
identified. 
The aim of this study was to use genome-wide information on gene expression profile 
induced by TNF-α in colon cancer cells and to elucidate additional features of EGCG beside 
its anti-inflammatory effect.  
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RESULTS AND DISCUSSION 
 
We have analysed the transcriptional response of a human colon adenocarcinoma cell 
line, HT29, which can be induced to express inflammatory features in vitro. EGCG, a catechin 
found in abundance in green tea, was used to reverse TNF-α-induced inflammation. Two 
thousand one hundred and fifty one genes of 14500 present in the chip were significantly 
regulated by at least one of the treatments. TNF-α significantly influenced 700 genes. 
Accordingly to its impact, genes were sorted by their change factors and only those > 0.5 
(up-regulated) and < -0.5 (down-regulated) were analysed (P value < 0.01). The analysis 
began with 179 genes where 151 were up-regulated and 28 down-regulated by TNF-α 
(Table 4). Among them, EGCG alone up-regulated 65 genes, down-regulated 45 genes, and 
did not affect 69. In the TNF-α/EGCG treated group, the number of genes up- or 
down-regulated by EGCG can also be visualized in Table 4 where red and green numbers 
represent up- and down-regulated genes, respectively. 
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Table 4. List of TNF-α-induced genes that were sensitive to EGCG 
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Table 4. List of TNF-α-induced genes that were sensitive to EGCG (CONTINUED) 
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Table 4. List of TNF-α-induced genes that were sensitive to EGCG (CONTINUED) 
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Table 4. List of TNF-α-induced genes that were sensitive to EGCG (CONTINUED) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2   Microarray GeneChip® Analysis of EGCG 
  63  
EGCG interferes with genes involved in immune response (Table 4) 
Several genes involved in immune response and inflammation were markedly 
up-regulated by TNF-α. EGCG down-regulated IL-8, GRO-α, MIP-2α, GRO-γ, IP-10 (CXC 
chemokines), and MIP-3α (CC chemokine) (Fig. 13), corroborating results described in 
Chapter 1. With regard to IL-8 and MIP-3α, the effect of EGCG was proven on the gene and 
on the protein level. Furthermore, other chemokines were affected by EGCG. Fractalkine, a 
CX3C chemokine, was dose-dependently down-regulated by EGCG while IP-9, a CXC 
chemokine, was inhibited in each concentration tested (Fig. 14; for TNF-α values see Table 4). 
These indicate that the effect of EGCG was not restricted to one single chemokine subfamily. 
Moreover, GCP-2, a CXC chemokine, was not altered by EGCG, suggesting that not all 
chemokines were affected by EGCG.  
 
Figure 13: DNA microarray analyses reveal EGCG-modulated chemokine expression 
Total RNA was extracted from HT29 cells stimulated with or without TNF-α and exposed to various concentrations 
of EGCG. cDNA was synthesized followed by hybridization to a microarray chip. Each treatment was done in 
quadruplicates.  
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Figure 14: EGCG influenced the 
expression of chemokines 
Dose-dependent down-regulation of IP-9, 
fractalkine and GCP-2 by EGCG in 
TNF-α−activated HT29 cells. Each treatment 
was performed in quadruplicates. 
 
 
 
 
 
 
 
 
Pro-inflammatory cytokines play an important role in the onset of inflammation 
(Brynskov et al., 1992). EGCG down-regulated several cytokines which were up-regulated by 
TNF-α including colony stimulating factor (CSF)-1 and natural killer cell transcription (NK)-4 
(also known as IL-32). CSF-1 controls the proliferation and differentiation of macrophages. In 
addition, it can function as an activator of macrophages and has been implicated as a 
contributor to disease severity in arthritic animal models (Sweet and Hume, 2003). We 
suggest that epithelial cells assist macrophages by expressing CSF-1. However, to avoid the 
activation of a large number of macrophages and to alleviate the severity of the inflammatory 
process, a limited expression of this cytokine should be present in the mucosa. EGCG 
reversed the expression of TNF-α-induced CSF-1, controlling macrophage activation and 
reducing the intensity of the disease. Furthermore, NK-4 was also markedly up-regulated in 
the presence of TNF-α. Since NK-4 induces the production of TNF-α, IL-8, and MIP-2 in 
different cell lines (Kim et al., 2005) and the latter cytokines are key molecules responsible for 
the progression of IBD (Eckmann et al., 1993a; Van Deventer, 1997), only restricted amount of 
these pro-inflammatory cytokines should be released into the mucosa. EGCG (at 6.25 and 
12.5 μM) reduced the expression of NK-4. However, 25 and 50 μM of EGCG slightly 
up-regulated its expression, suggesting that high concentrations of EGCG rather stimulated 
NK-4. The regulation of TNF-α, IL-8 and MIP-2 by EGCG is described in Chapter 1. 
Interferon (IFN)-γ participates in a large array of cellular responses including the 
induction of efficient antigen processing for MHC-mediated antigen presentation, which play 
defined roles in pathogen resistance, and in cell proliferation and apoptosis. Its response is 
itself regulated by interaction with responses to other cytokines including TNF-α (Boehm et al., 
1997). IFN-dependent signalling involves members of four protein families, including the Type 
I and II IFN receptors (IFNGR); the receptor-associated Janus protein tyrosine kinases (Jaks); 
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the signal transducers and activators of transcription (STAT) proteins; and members of the 
interferon regulatory factor (IRF) family of transcription factors (Ramana et al., 2000). Over 
200 genes are known to be regulated by IFN-γ, however, only a few were expressed in 
HT29 cells and up-regulated in the presence of TNF-α (Table 4). EGCG, in at least one 
concentration, modulated all four members of the IFN signalling. The expression of IFNGR1 
and 2, IRF1, and Jak1 were slightly up-regulated in the presence of 12.5 μM of EGCG 
compared to TNF-α. As deduced by these results, EGCG (at one concentration) was able to 
activate INF-γ pathway. Furthermore, other molecules belonging to this pathway were also 
affected. For example, interferon-γ-inducible protein (IFI)-16, a molecule involved in the 
modulation of p53 and cell proliferation, was dose-dependently down-regulated by EGCG. In 
the presence of EGCG alone, its expression was further down-regulated. Similar effect were 
observed on the expression of interferon-induced protein with tetratricopeptide repeats (IFIT)-1 
and -3, cellular components of the immune response, where EGCG also reduced their 
expression. Another interferon-inducible protein, guanylate binding protein (GBP)-1, was 
increased in cells stimulated with TNF-α. GBP1 is characterized by its ability to specifically 
bind to the guanine nucleotide GTP, exerting GTPase activities. It is selectively induced by 
cytokines including IFN-γ and TNF-α, but not by chemokines. It is thought that an elevated 
expression of GBP1 could inhibit cell proliferation and induce cell adhesiveness for 
monocytes. In addition, GBP1 was identified as a novel molecular marker of the inflammatory 
cytokine-activated phenotype of endothelial cells in vitro and in vivo (Lubeseder-Martellato et 
al., 2002). In our study, EGCG dose-dependently down-regulated the expression of GBP1. 
Taking together, these results suggest that EGCG interferes in IFN-γ-induced immune 
responses, increasing cell proliferation and reducing cell adhesiveness for immune cells. 
Binding of a given cytokine (e.g. IFN-γ) to its receptor (e.g. IFNGR) leads to the 
recruitment and activation of STAT proteins which, after being activated by tyrosine 
phosphorylation, migrate into the nucleus and mediate transcription of cytokine-specific genes. 
STATs are key transcription factors which play vital roles in IFN signalling pathway (Ramana 
et al., 2000). STAT1 is involved in several processes: (1) IκB kinase/NF-κB cascade; (2) STAT 
protein nuclear translocation; (3) caspase activation which leads to apoptosis; (4) regulation of 
cell cycle (proliferation); (5) regulation of transcription; and (6) response to pathogen or 
parasite (Ramana et al., 2000). In our experiment, the expression of STAT1 was up-regulated 
upon TNF-α stimulation (change factor of 0.66) and significantly reduced by EGCG (50 μM 
induces a change of -1.05 fold compared to TNF-α). Treating cells only with EGCG also 
diminished its expression as shown in Table 4. We infer that TNF-α-induced STAT1-signal 
transducer activities could be reversed in the presence of high concentrations of EGCG. 
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Moreover, a key enzyme in the biosynthesis of prostaglandins, COX-2, was also 
expressed in HT29 cells and markedly increased in cells exposed to TNF-α. EGCG 
dose-dependently reduced its expression, confirming previous results presented in Chapter 1. 
Lymphotoxin beta (LTB, also known as TNFC), a type II membrane protein of the TNF family, 
is an inducer of the inflammatory response and involved in the normal development of 
intestinal lymphoid tissue. Data currently available indicate that the inhibition of LTB receptor 
signalling leads to the suppression of intestinal inflammation by altering the local intestinal 
lymphoid microarchitecture (Spahn and Kucharzik, 2004). Our results showed that the 
expression of LTB was drastically up-regulated upon TNF-α stimulation and EGCG 
dose-dependently diminished it. Admittedly alteration of the intestinal lymphoid tissue is 
undesirable, yet EGCG might merely reestablish normal LTB levels, and thus, contribute to the 
prevention of chronic inflammation. 
In summary, EGCG had shown a heterogeneous effect on the expression of genes 
involved in immune modulation and inflammatory processes in HT29 cells (Fig. 15). It was 
able to (1) reduce chemokine expression and production, impairing the migration of immune 
cells; (2) inhibit cytokines such as CSF-1 and NK-4; (3) act on IFN-γ signalling pathway, 
regulating IFNGR, IRF, JAK1, STAT1 and GBP-1; (4) affect the arachidonic acid metabolism 
by inhibiting COX-2 and further prostaglandin production; and (5) modulate the intestinal 
immune system, reducing LTB signalling. 
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Figure 15: Effects of EGCG in TNF-α-stimulated HT29 cells 
Model of molecular events, as deduced from the array data. Genes labelled green were down-regulated by TNF-α 
and subsequently down-regulated by TNF-α / EGCG. Genes labelled blue were up-regulated by TNF-α and further 
up-regulated by TNF-α / EGCG. Genes labelled red were up-regulated by TNF-α and down-regulated or unaffected 
by TNF-α / EGCG. For abbreviations, see List of Abbreviations. 
 
NF-κB pathway is modulated by EGCG 
NF-κB comprises a family of inducible transcription factors (p50 or NF-κB1, p52 or 
NF-κB2, p65 or RelA, Rel, and RelB) which is involved in the regulation of important immune 
processes such as innate immunity, immune surveillance, and antigen presentation. In 
addition, NF-κB also participates in harmful processes in pathogenesis, i.e. in inflammation 
and cancer (Shishodia and Aggarwal, 2004). It is a heterodimer which usually consists of p65 
and p50 (Barnes and Karin, 1997; Yamamoto and Gaynor, 2001). In unstimulated cells, NF-κB 
is present in a resting state in the cytoplasm associated with the inhibitor of NF-κB (IκB) family 
(IκBα, IκBβ, IκBε); only when these cells are stimulated (e.g., by cytokines as TNF-α and 
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IL-1β), NF-κB is activated and translocated into the nucleus where it binds to specific 
sequences in the promoter regions of target genes to activate gene expression. Several 
anti-inflammatory substances exert their effects by inhibiting components of the IκB-α/NF-κB 
cascade (Yamamoto and Gaynor, 2001).  
In our experiment, some components of the IκB/NF-κB cascade were induced with 
TNF-α, including RelB, NF-κB1, NF-κB2, IκBα, IκBβ and IκBε (Table 4). The expression of 
RelB was slightly up-regulated in the presence of low concentrations of EGCG and reduced 
with high concentrations. For NF-κB1 or p50, its expression was not altered by EGCG 
compared to TNF-α. NF-κB2 (p52) expression was drastically up-regulated with low 
concentrations of EGCG (6.25-25 μM). None of these genes were affected when cells were 
treated only with EGCG. p65 (RelA) was not found to be regulated by the treatment. It was 
present in the microarray; however, it possibly was excluded during the filtering due to a low 
intensity signal or P > 0.01. Furthermore, the IκB family were also expressed in HT29 cells 
upon TNF-α stimulation. IκB-α was 6.76-fold up-regulated in the presence of the stimulus. 
EGCG inhibited its expression in each concentration tested. IκB-β was only 1.78-fold 
up-regulated by TNF-α and EGCG rather induced its expression compared to TNF-α. With 
regard to IκB-ε, its expression was 3.10-fold increased with TNF-α. EGCG up-regulated its 
expression in each concentration tested. EGCG reversed TNF-α-induced IκB-α expression, 
while did not affect or rather increased the expression of IκBβ and IκBε, suggesting that it 
might be able to prevent IκBα degradation.  
 
EGCG regulates apoptosis by modulating TNF-α signalling pathway (Table 4 and 
Fig. 15) 
TNF-α plays an essential role in the activation of caspases and death receptors which 
lead to apoptosis (Aggarwal, 2003). A dysregulation in the aforementioned process is 
associated with many pathological conditions such as chronic inflammation and cancer 
(Zangemeister-Wittke and Simon, 2001). 
TNF-induced responses are mediated through one of its receptors, TNFR1 or TNFR2. 
TNF-α itself is known to drive TNFR1 expression. Upon binding of TNF-α, trimerisation of 
TNFR1 leads to the recruitment of several proteins to the cytoplasmic “death domain” of the 
receptor. Association of receptor-interacting protein (RIP) and TNFR-associated factor 
(TRAF)-2 to TNFR-associated death domain protein (TRADD) activates two transcription 
factors: NF-κB and activator protein (AP)-1. AP-1-mediated gene induction results from 
activation of c-Jun N-terminal kinase (JNK) via TRAF2. The transcriptional activity of NF-κB 
and AP-1 results in suppression of apoptosis. On the other hand, recruitment of fas-associated 
Chapter 2   Microarray GeneChip® Analysis of EGCG 
  69  
death domain protein (FADD) to TRADD allows activation of “initiator” caspases (e.g. 
caspase 8). The latter indirectly activates the release of apoptogenic mitochondrial factors 
such as cytochrome c. The association of ATP and the apoptotic protease activating factor 
(APAF)-1 to cytochrome c leads to the activation of caspase 9 which in turn activates 
executioner caspases (e.g. caspase 3), leading to apoptosis. Caspase 3 can activate caspase 
6, which is involved in the induction of cell shrinkage. Apoptosis inhibitors such as B-
cell/lymphoma (Bcl)-2 or Bcl-xL are able to inhibit the caspase cascade downstream of 
mitochondria (Papadakis and Targan, 2000; Aggarwal, 2003). 
We observed in our experiments that genes of the TNF-signalling pathway were 
up-regulated with TNF-α, including TNF-α, TNFR1, TRAF2, TRAF family member-associated 
NF-κB activator (TANK), programmed cell death (PDCD)-6, TNF-related apoptosis-inducing 
ligand (TRAIL), TRAIL receptor (TRAILR)-2, x-linked inhibitor of apoptosis (xiap) associated 
factor (XAF)-1, TNF-α-induced protein (TNFAIP)-2 and -3, death receptor (DR)-6, myeloid cell 
leukaemia sequence (MCL)-1, caspase (CASP)-6, Bcl-3, and apoptosis inhibitor (API)-2. 
TNF-α expression itself was only 3.61-fold increased after TNF-α stimulation. This contrasts 
with a substantially higher increase determined by quantitative RT-PCR (see Chapter 1). 
However, the effect of EGCG on this gene was similar where EGCG dose-dependently 
down-regulated its expression. In the absence of the stimulus, EGCG down-regulated TNF-α 
at any concentration. The major effect was observed with the lowest concentration. With 
regard to TNFR1, its expression was weakly induced upon TNF-α stimulation (0.56-fold). In 
addition, EGCG was not able to reverse TNF-α-induced gene expression. Overall, the 
expression level of this receptor in each concentration tested was similar to that of the 
stimulus or slightly higher. Treating unstimulated cells with 50 μM of EGCG led to an 
up-regulation of TNFR1 (0.57-fold). Furthermore, the expression of TRAF2, a regulator of 
NF-κB, was also increased in the presence of TNF-α (1.01-fold). Activated cells treated with 
EGCG reversed the effect of TNF-α whereas unstimulated cells exposed to EGCG resulted in 
an up-regulation of this gene. TANK, an inhibitor of TRAF proteins, was induced by TNF-α 
(0.63-fold). Lower concentrations of EGCG increased its expression. Taken together, EGCG 
was able to affect TNF-α signalling pathway by inhibiting the expression of TNF-α and 
modulating its receptor TNFR1. In addition, TRAF2, a regulator of anti-apoptotic signals of 
TNF receptors, was also reduced by EGCG suggesting that less TRAF2 is available for 
receptor binding. We deduced that anti-apoptotic signals may be slowed down in the presence 
of EGCG that thus augments apoptosis. Concomitantly, EGCG up-regulated the inhibitor of 
TRAF, TANK. However, unstimulated cells treated with EGCG have shown an increase in 
TRAF2 which could be interpreted as a preventive effect against apoptosis. Since these data 
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express only effects occurring on the gene level, more experiments need to be done to 
confirm this hypothesis. 
During the normal development of multicellular organisms, cell proliferation, 
differentiation and cell death are tightly balanced and are regulated by different regulators. 
Programmed cell death is a genetically controlled process involved in apoptosis and 
responsible to remove 'unwanted' cells from the organism (Krebs et al., 2002). Programmed 
cell death (PDCD)-6 was found to be 1.72-fold up-regulated in response to TNF-α in 
HT29 cells. However, EGCG inhibited it in each concentration tested. Moreover, unstimulated 
cells exposed to EGCG induced the expression of this gene. These results indicate that 
EGCG is able to regulate programmed cell death machinery induced in inflammation. Since 
the epithelium is constantly exposed to various pathogens, immune cells are constantly 
present in the mucosa. EGCG may increase the expression of cell death proteins in epithelial 
cell to assist with the normal cellular response, cleaning 'unwanted' cells from the mucosa. 
TRAIL, a member of TNF ligand proteins, is involved in apoptosis by binding to and 
inducing oligomerization of its cell-membrane death receptors (DR4 and DR5), triggering the 
activity of CASP8 and apoptosis (Guo and Bhalla, 2002). Furthermore, studies demonstrated 
a relationship between NF-κB and TRAIL (Wajant, 2004). It was reported that NF-κB 
prevented TRAIL-induced apoptosis in human hepatoma through a TRAIL-activated TRAF2-
NIK-IKK pathway (Kim et al., 2002). In our experiment, TNF-α induced the expression of 
TRAIL (1.01-fold increased) which was dose-dependently down-regulated by EGCG. 
Exposure of unstimulated cells to EGCG leaded to a subsequent repression of this gene. 
Moreover, TRAILR2, also known as DR5, was likewise induced by TNF-α (1.99-fold) and 
further dose-dependently up-regulated by EGCG. No changes on the expression level of this 
gene were observed after treating unstimulated cells with EGCG. Our findings suggest that 
EGCG may increase cell surveillance through two ways: (1) direct inhibition of TRAIL-induce 
apoptosis; and (2) activation of NF-κB cascade by up-regulating RelB and p52. However, the 
effect of EGCG on TRAILR2 still remains to be addressed. Another gene up-regulated upon 
TNF-α stimulation was XAF1. This gene antagonizes the anticaspase activity of xiap (Liston et 
al., 2001) and augments TRAIL-induced apoptosis (Leaman et al., 2002). In activated cells, 
EGCG had shown an inhibition of the expression of this gene in each tested concentration. In 
addition, EGCG alone dose-dependently down-regulated it. Furthermore, DR-6, a member of 
the TNF receptor superfamily, has been shown to activate NF-κB, MAPK8/JNK, and induce 
cell apoptosis. It has been demonstrated that DR-6 interacts with TRADD activating caspase 
8, which in turn activates the NF-κB pathway (Pan et al., 1998). TNF-α induced the expression 
of DR6 in HT29 cells (1.09-fold increased). In the presence of EGCG, its expression was 
rather up-regulated compared to TNF-α. Exposure of unstimulated cells to high concentrations 
Chapter 2   Microarray GeneChip® Analysis of EGCG 
  71  
of EGCG also led to an increase of its expression. We infer that EGCG may exerts a 
preventive effect against apoptosis by affecting TRAIL/DR5 and XAF1 expression, however, 
not all apoptotic inducers are targets for EGCG. 
TNFAIP2, also known as B94, is a cytokine-inducible immediate early gene identified 
as a TNF-α-inducible transcript in human endothelial cells (Sarma et al., 1992). B94 was 
shown to be expressed in the intestine (Rusiniak et al., 2000), a finding that is well in 
agreement with our data presented in this report. We found that TNFAIP2 was moderately 
up-regulated in the presence of TNF-α (8.67-fold) in HT29 cells. EGCG was able to reduce its 
expression. Since its function in the intestinal environment is still not elucidated, we were not 
able to speculate about the effects of EGCG on this gene. Furthermore, another member of 
TNF-α-inducible protein was found to be expressed in HT29 cells. TNFAIP3, also known as 
A20, has been implicated in the negative regulation of the NF-κB activation pathway (Lee et 
al., 2000) and TNF-mediated programmed cell death. It can inhibit TNF-induced apoptosis by 
disrupting recruitment of death domain-containing adapter proteins TRADD and RIP to the 
TNF receptor 1 signalling complex (He and Ting, 2002). Upon TNF-α stimulation, the 
expression of TNFAIP3 was moderately up-regulated (13.35-fold). EGCG inhibited its 
expression in each tested concentration where the strongest effect was obtained with the 
highest concentration (50 μM = 9.48-fold). Since the effects of EGCG at low concentrations 
were not markedly different from that of TNF-α, EGCG did not reverse TNFAIP3 anti-apoptotic 
effects in these concentrations. However, we can not exclude the possibility that anti-apoptotic 
proteins may be negatively affected by 50 μM of EGCG.  
MCL1, a member of the Bcl2 family, functions as an apoptotic regulator increasing cell 
survival (Leu et al., 2004). Its expression was 1.23-fold up-regulated in the presence of TNF-α. 
Treating TNF-α-induced cells with EGCG led to a dose-dependent increase of its expression. 
Unstimulated cells exposed to EGCG also increased the expression of MCL1, but only at high 
concentrations (25 and 50 μM). These results indicate that EGCG has a protective effect 
against apoptosis in both inflammation and normal cellular response. Another anti-apoptotic 
gene known as Bcl3 was expressed in HT29 cells. Bcl3, a member of the IκB family, was 
4.94-fold up-regulated upon TNF-α stimulation. Low concentrations of EGCG increased its 
expression whereas 50 μM reduced it. Interestingly, unstimulated cells treated with 50 μM of 
EGCG augmented its expression. These findings suggest that EGCG induces cell survival in 
inflammatory responses by affecting the NF-κB cascade. Moreover, API2 was shown to be 
markedly up-regulated by TNF-α (24.30-fold). However, EGCG neither drastically induced nor 
reduced its expression. Another gene belonging to the caspase cascade, CASP6, was 
unexpectedly down-regulated with TNF-α, effect of which was intensified by EGCG, indicating 
that both TNF-α and EGCG would lead to cell surveillance. 
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Taking together, EGCG had shown heterogeneous effects against apoptosis through 
the modulation of several genes involved in different pathways. In one hand, regulating genes 
of the TNF/TNFR1 signalling; and in the other hand, directly affecting death receptors, and 
thus, the caspase cascade. By regulating TNF/TNFR1 pathway, EGCG inhibited genes 
involved in the activation of CASP8 in addition to the modulation of others that activated the 
NF-κB cascade. EGCG also unexpectedly modulated genes that induce apoptosis, indicating 
that depending of the needs it may induce cell surveillance and apoptosis in epithelial cells. 
 
EGCG regulates cell adhesion in HT29 cells (Table 4 and Fig. 15) 
Adhesion molecules regulate the influx of immune cells such as leukocytes in normal 
and inflamed gut. This process is mediated by adhesion receptor families named integrins, 
which are particularly important in biological processes that require rapid modulation of 
adhesion and de-adhesion (Bazan-Socha et al., 2005). In many inflammatory diseases such 
as IBD, most of the adhesion factors are up-regulated (van Assche and Rutgeerts, 2002). 
Studies have shown neutrophilic infiltrates within the colonic epithelium of biopsies taken 
during active diseases periods (Parkos, 1997). Results obtained from our microarray analysis 
indicated that HT29 cells were able to express some genes involved in cell-cell adhesion, 
including CD11b, CD51, intracellular adhesion molecule (ICAM)-1, ICAM-4 and CD156. All 
were up-regulated upon TNF-α activation (1.96; 1.32; 7.79; 3.35; and 1.11, respectively) and 
regulated by EGCG. The expression of CD11b, CD51, and CD156 (also known as integrin 
alpha M, V, and a disintegrin and metalloproteinase domain (ADAM)-8 respectively) were 
up-regulated while ICAM-1 and -4 were down-regulated by EGCG. The latter findings indicate 
that, in addition to the chemokine inhibition (e.g. IL-8) described in Chapter 1, EGCG can also 
interfere with leukocyte infiltration by diminishing ICAM, and therefore, ameliorate 
inflammatory response. We have no worthy explanation for the aforementioned effect of 
EGCG on CD11b and CD51. The former is mainly expressed in leukocytes and interacts with 
ICAM-1 upon stimulation. However, we suggest that EGCG would contra-balance its inhibitory 
effect on ICAM-1 by increasing the expression of CD11b. With regard to CD156, it is 
expressed in leukocytes and B cells. It interacts with integrins through its disintegrin-like 
domain, acting as cellular counter receptor (Bridges and Bowditch, 2005). EGCG would 
increase this interaction, and thus, the function of CD156. 
Moreover, gap-junctions and tight-junctions proteins are also involved in cell adhesion. 
The former are protein-lined channels between adjacent cells that allow the direct cell-cell 
passage of small cytoplasmic molecules such as ions, metabolic intermediates, and second 
messengers. The latter are continuous seals (ribbon-like bands) that connect adjacent 
epithelial cells. They serve as a physical barrier to prevent leakage of fluid across the cell 
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layer. In our experiment, three genes involved in both mechanisms were found to be 
up-regulated with TNF-α: gap junction protein beta (GJB)-3; claudin (CLDN)-1 and -18. The 
expression of GJB-3 was increased in the presence of EGCG. In addition, unstimulated cells 
exposed to EGCG, also up-regulated this gene, however, only at high concentrations. 
Furthermore, CLDN-1 was down-regulated by EGCG and its expression was not modulated in 
unstimulated cells exposed to the compound. The expression level of CLDN-18 was increased 
when high concentrations of EGCG were used, and it was also elevated in unstimulated cells 
treated with high concentrations of the substance. We infer that EGCG may affect 
gap-junctions to increase intercellular metabolic and electronical communication, and thereby, 
augmenting response to external factors. In addition, increasing the expression of CLDN-18, 
EGCG would be able to increase tight junction strands in epithelial cells, and therefore, 
prevent fluid from passing freely through the injured cell layer. Since CLDN-1 was shown to be 
overexpressed in human colon cancer cell lines (Niwa et al, 2001), we suggest that EGCG 
may have preventive effects also on colon cancer by reducing CLDN-1.  
In summary, our results indicate that EGCG can reduce inflammation by affecting 
leukocyte infiltration through the reduction of adhesion molecules. In addition, EGCG may 
regulate cell adhesion by increasing gap- and tight-junction activities between adjacent 
epithelial cells. 
 
EGCG regulates tissue repair and remodelling (Table 4 and Fig. 15) 
Extensive remodelling of the extracellular matrix (ECM) is often found in inflammatory 
lesions, for example, in IBD. Molecules belonging to the ECM suffer profound alteration and 
their cell surface receptors have been found in a number of inflammatory processes. In 
addition, cell-ECM interactions are regulators of these pathological sequences (Smith et al., 
1997). Laminins are basement membrane components thought to mediate the attachment, 
migration and organization of cells into tissues during embryonic development by interacting 
with other ECM components. In the intestinal tract, laminins influence enterocyte differentiation 
(Beaulieu, 1997). Laminin (LAM)-5 is an integral part of the anchoring filaments that connect 
epithelial cells to the underlying basement membrane. It is formed by three subunits (LAMC2; 
LAMA3; and LAMB3) and beside cell differentiation, it is thought to be involved in cell 
adhesion and signal transduction (Katayama and Sekiguchi, 2004). We found that LAMC2, 
LAMA3 and LAMB3 were up-regulated after TNF-α stimulation (4.39; 2.12; and 1.29-fold, 
respectively). EGCG increased the expression of LAMC2 and LAMB3 in all concentrations 
tested. The expression of LAMA3 was down-regulated upon EGCG treatment. In addition, 
EGCG induced the expression of LAMC2 and LAMA3 but not of LAMB3 in unstimulated cells. 
Furthermore, collagen (COL)16A1, a nonfibril-forming collagen, which serves to maintain the 
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integrity of the ECM, was also induced upon TNF-α activation (0.81-fold). EGCG augmented 
its expression when a concentration range of 12.5 to 50 μM was used. EGCG alone did not 
affect its expression. Moreover, matrix metalloproteinase (MMP)-7, an enzyme implicated in 
normal and pathologic tissue remodelling processes, was found to be expressed in HT29 cells 
(Table 4). MMP-7 is involved in wound healing, and studies in mice suggest that it regulates 
the activity of defensins in intestinal mucosa (Wilson et al., 1999). We observed that the 
expression of MMP-7 was increased in TNF-α-stimulated cells (2.59-fold). EGCG up-regulated 
its expression with the increase of the concentration. In addition, its expression was further 
increased in unstimulated cells exposed to high concentrations of EGCG. Under TNF-α 
stimulation, the expression of CD87, known as plasminogen activator urokinase receptor 
(PLAUR), was also up-regulated (1.42 fold). At low concentrations, EGCG rather reduced its 
expression while at high concentrations it was drastically increased. Additionally, its 
expression was increased in unstimulated cells treated with high concentrations of EGCG. 
Since CD87 is involved in the regulation of proteolysis, cell migration and chemotaxis, and 
growth control; and upon activation, plasminogen augments the degradation of ECM (Wang et 
al., 2004), we infer that low concentrations of EGCG would rather reduce the activity of CD87, 
reducing plasminogen-induced ECM degradation. At high concentrations, EGCG would 
drastically increase the CD87 functions, and thereby, either induce cell migration and 
chemotaxis, ECM degradation through the activation of plasminogen or even stimulate 
epithelial cell growth. Our results indicate that EGCG is able to control and reverse ECM 
degradation induced by TNF-α through the modulation of LAM5 and MMP-7, however, 
depending on the concentration used, EGCG can also stimulate ECM degradation via 
plasminogen activation. We suggest that EGCG may promote tissue repair and wound healing 
by increasing the expression of molecules involved in cell differentiation and tissue 
remodelling. In addition, EGCG may assist epithelial cells in their function as maintainers of 
the ECM integrity. Although EGCG, at high concentrations, drastically induced CD87 activity, 
these effects may contrabalance the inhibitory effect on other genes such as chemoattractant 
genes, and thus, contributing to physiological functions regulating the quantity of immunocytes 
present in the mucosa. 
In addition to the aforementioned genes, three other genes were found to be indirectly 
involved in the maintenance of the ECM integrity such as syndecan (SDC)-4, protease 
inhibitor (PI)-3, and p62 (also known as sequestosome 1). TNF-α induced the expression of all 
above mentioned genes (4.65; 18.84; and 8.74-fold, respectively). The expression of SDC-4, a 
transmembrane (type I) heparin sulphate proteoglycan, was dose-dependently reduced by 
EGCG which did not regulate it in unstimulated cells. Since SDC-4 mediates 
anti-thrombin-induces chemotaxis of human lymphocytes and monocytes (Kaneider et al., 
2002), we imply that EGCG affects inflammatory response by reducing molecules involved in 
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immunocyte recruitment. Furthermore, EGCG reduced TNF-α-induced PI3, a specific human 
neutrophil elastase inhibitor. Concentrations of 6.25, 12.5, and 50 μM of EGCG 
down-regulated PI3 while 25 μM of the substance increased its expression to 21.80-fold. 
Conversely, a down-regulation of the gene was observed in unstimulated cells treated with low 
concentrations of EGCG. Since an overexpression of PI3 protected human endothelial cells 
from neutrophil elastase-induced damage and reduced IL-8 production in response to TNF-α 
(Henriksen et al., 2004), we infer that only 25 μM of EGCG may induce reparation of 
damage-tissue and restore TNF-α-induced apoptosis. In addition, EGCG would indirectly 
interfere with neutrophil migration by increasing PI3 expression and reducing IL-8 (Chapter 1). 
Moreover, the expression of p62, a gene involved in ubiquitin proteasome degradation, was 
also modulated by EGCG. Low concentration of EGCG (6.25 and 12.5 μM) rather increased 
its expression while high concentrations of the compound down-regulated it. Interestingly, only 
6.25 and 50 μM of EGCG were able to increase its expression in unstimulated cells. 
Ubiquitination of cellular proteins is a crucial feature in regulation of signal transduction and 
cell cycle progression through ubiquitination-dependent proteosomal degradation of important 
cellular proteins (Vadlamudi et al., 1996). We suggest that EGCG at low concentrations may 
favour proteosomal degradation while high concentrations would rather inhibit it.  
 
Several signalling pathways are affected by EGCG (Table 4 and Fig. 15) 
TNF-α induced the expression of several genes involved in different pathways, 
including growth factor signalling, cell cycle and proliferation, AP-1, MAPK, PI3K, PKC, 
PTPase, and GTPase signalling. Firstly, EGCG up-regulated genes associated with growth 
factor signalling (e.g., LIF, PDGF2, PTHLH, GDF15, and SMAD3) and cell cycle/proliferation 
(e.g., p21, PLK2, DCBLD2, and EMP1). Secondly, EGCG regulated specific genes of various 
signalling pathways: AP-1 (JUNB and JUND were increased); MAPK (ERK3 was not 
significantly affected; MEK3 was increased; MEKK1 was increased with low concentrations of 
EGCG); PI3K (FT1, PIK3R1 were down-regulated); PKC (NOXA was increased); PTPase 
(PTPRH was augmented); and GTPase (RHOB was up-regulated; and RASAL2 was 
inhibited). We concluded that EGCG is able to regulate cell cycle, differentiation, epithelial 
regeneration, cell growth, in addition to induce wound healing; however, without inducing 
apoptosis. Since these data are related only to the gene level, further analysis should be 
elaborated in order to obtain more information about the posttranslational modification such as 
protein expression.  
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CONCLUSION 
 
In the present study, we evaluated the effect of EGCG on the expression of an array of 
genes involved in several processes such as immune response and inflammation, apoptosis, 
cell adhesion, ECM degradation in addition to its interference in specific signalling pathways. 
Our findings clearly establish that EGCG influences specific sets of TNF-α-inducible genes 
resulting in anti-inflammatory effects. Additionally, we provided evidence that EGCG has a 
heterogeneous effect on these cellular processes. Since this study was performed with only 
one time point (6 hours), we could not identify genes that changed in expression with time of 
exposure. Furthermore, microarray analysis deliver a general screening of possible affected 
genes and indicate potential new leads to mechanisms explaining the biological activity of 
EGCG. However, data should be confirmed by using other methods, including RT-PCR 
analysis and protein expression. Moreover, to conclude about the effects of EGCG in a 
specific pathway, the analysis of genes should be performed as a group rather than a single 
gene. Overall, studying expression changes of thousands of genes has provided increased 
insight into the mechanism of action of EGCG in intestinal inflammation, helping us to 
understand how this compound can be used to prevent or treat inflammatory diseases as IBD. 
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Chapter 3                                              Plant extracts modulate inflammatory processes in vitro 
  78  
ABSTRACT 
 
Extracts from Boswellia serrata (BS) and Rosmarinus officinalis (RO) have been used to treat 
inflammatory conditions, including arthritis and inflammatory bowel disease (IBD). In this 
study, HT29 cells were used to investigate the effects of BS and RO on activated intestinal 
epithelial cells. The in vitro “inflammatory” condition was induced with tumor necrosis factor 
(TNF)-α and interleukin (IL)-1β. Activated cells were treated with the indicated extracts to 
study their effects on cellular inflammatory processes. The secretion of chemokines such as 
IL-8 and MIP-3α was determined by ELISA. Expression levels of genes involved in 
inflammation were quantified by real time RT-PCR. NF-κB binding activity was determined by 
EMSA. IκB-α protein expression was measured by immunoblotting. BS and RO 
dose-dependently inhibited the synthesis of IL-8 and MIP-3α by activated cells. Concomitantly, 
BS and RO down-regulated genes involved in inflammatory pathways. NF-κB binding activity 
was reduced in the presence of RO, but not of BS. The effect of TNF-α on IκB-α was partially 
reversed by RO while BS had no effect. This study shows the anti-inflammatory effects of BS 
and RO at different levels in HT29 cells: on the expression of “inflammatory” genes, by 
affecting NF-κB binding and IκB degradation, and by inhibiting the production of chemokines. 
Therefore, BS and RO extracts might have a preventive utility in gastro-intestinal disorders 
and may be further applied in the treatment of inflammatory diseases, including IBD. 
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INTRODUCTION 
 
The intestinal epithelium forms a physical barrier that protect internal milieu of the host 
from foreign antigens, eliciting an appropriate immune response. Cells of the gastrointestinal 
tract, including leukocytes, regulate the immune and inflammatory responses (Kagnoff, 1996; 
Fiocchi, 1997b). Defects in the mechanisms that control the defence against pathogenic 
antigens are responsible to initiate an excessive immunological response that may lead to 
tissue destruction and further intestinal inflammation (Nagler-Anderson, 2001).  
During the course of intestinal inflammation, e.g. in IBD, epithelial cells develop 
additional functions which are normally attributed to inflammatory cells. One of these 
characteristics is that in response to several stimuli, such as TNF-α and IL-1β, epithelial cells 
initiate an exacerbated production of chemokines which are involved in cell migration (Stenson 
and MacDermott, 1989; MacDermott, 1994). Chemokines are small chemoattractant 
molecules responsible in activating and recruiting PML to the injured site (Baggiolini and 
Moser, 1997; Dwinell et al., 1999). IL-8, MIP-2, GRO-α and GRO-γ belong to the 
CXC chemokines which mainly attract and activate neutrophils. MIP-3α, a member of the 
CC chemokine subfamily, is able to activate and recruit monocytes, T lymphocytes and DC. All 
these molecules are involved in inflammation and contribute to the perpetuation of 
inflammatory processes (Ajuebor and Swain, 2002). 
Beside these molecules, other mediators, including those of the arachidonic acid 
metabolism, are also relevant in intestinal inflammation. COX-2, the inducible form, is a 
key-enzyme in the conversion of arachidonic acid to prostaglandins. It is overexpressed in 
several colon cancers and at sites of inflammation (Parker et al., 1997; Singer et al., 1998). 
TNF-α and IL-1β are able to induce the expression of this enzyme in a variety of cell lines 
including the human colon epithelial cells. 
Extracts from Boswellia serrata Roxb., a large branching tree belonging to the 
Burseraceae family, have been studied in many inflammatory conditions, including arthritic 
diseases and IBD (Han, 1994; Ammon, 2002). BAs, the major active components present in 
the gum resin, are responsible for the anti-inflammatory properties of the extract (Ammon et 
al., 1993; Gupta et al., 1997; Gupta et al., 2001; Krieglstein et al., 2001). Clinical trials in 
chronic and ulcerative colitis revealed that gum resin preparation from BS improved symptoms 
of these diseases with minimal side effects (Gupta et al., 1997; Gupta et al., 2001). In a study 
on Crohn’s disease, BS proved to be as efficient as mesalazine (Gerhardt et al., 2001). 
Furthermore, in an experimental model of ileitis, the extract of BS and one of its active BAs, 
dose-dependently decrease rolling and adherence of leukocytes in ileal submucosal venules, 
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reducing macroscopic and microcirculatory features of inflammation (Krieglstein et al., 2001). 
The mechanism of action of the extract and its BAs is incompletely understood. Some studies, 
however, demonstrated that their anti-inflammatory effects were mediated by the inhibition of 
5-lipoxygenase (5-LOX) which causes suppression of leukotriene synthesis (Safayhi et al., 
1992; Ammon et al., 1993; Safayhi et al., 1995; Sailer et al., 1998). 
Rosmarinus officinalis L., a bushy shrub belonging to the family Labiatae, has 
commonly been used to flavour or to preserve food. RO is known for its anti-oxidative (Ozcan, 
2003), anti-bacterial (Del Campo et al., 2000), anti-mutagenic (Minnunni et al., 1992), and 
chemopreventive (Plouzek et al., 1999) properties which are attributed to its active 
components rosmarinic acid and phenolic diterpenes (e.g. carnosic acid, carnosol, rosmanol). 
As shown in mouse macrophages, RO exerts anti-inflammatory effects on nitric oxide 
production through the action of its component, carnosol (Chan et al., 1995). Another study 
confirmed this finding and revealed that the suppression of nitric oxide synthase was 
NF-κB-dependent (Lo et al., 2002).  
In the present study, we evaluate the anti-inflammatory effects of BS and RO extracts 
on the TNF-α and/or IL-1β-stimulated human colon adenocarcinoma cell line HT29. Here we 
show that BS and RO inhibit specific chemokines and modulate several inflammatory genes, 
suggesting that they can ameliorate intestinal inflammation. Additionally, data presented 
herein demonstrate that RO, but not BS, reduce the binding activity of NF-κB to its κB element 
in the promoter sequence, suggesting that it is able to impair the transcription of inflammatory 
genes. 
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RESULTS 
Evaluation of the impact of plant extracts on cell viability 
In order to evaluate the cytotoxicity of the cell treatments and of the extracts, the LDH 
activity was measured in cell culture supernatants (Fig. 16). EGCG, presented in Chapter 1 
and 2, was used as a reference substance. The amount of released LDH was similar in the 
different treatments, except at 50 μg/mL of BS, indicating that TNF-α/IL-1β and BS or RO did 
not significantly affect the cell viability.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Effects of BS and RO on the LDH release by HT29 cells after 24 h of culture 
Cells were stimulated with TNF-α (100 ng/mL) and IL-1β (5 ng/mL) in the presence of varying concentrations of 
extracts. Amounts of released LDH are expressed in U/L. Similar data have been obtained in two independent sets 
of experiments. 
 
IL-8 and MIP-3α production is dose-dependently inhibited by BS and RO 
IL-8 and MIP-3α production in HT29 cells were measured to investigate the in vitro 
intestinal inflammatory response. Cells responded to TNF-α and/or IL-1β by producing high 
amounts of IL-8 and MIP-3α (Fig. 17); untreated cells did not secrete detectable amounts of 
these chemokines. In the presence of IL-1β alone (5 ng/mL), the synthesis of IL-8 was weakly 
increased compared to TNF-α/IL-1β (Fig. 17A). In cells stimulated only with TNF-α 
(100 ng/mL), the production of IL-8 was stronger than that observed by IL-1β. The strongest 
effect was obtained with TNF-α/IL-1β, which drastically raised the production of IL-8 to 
~12000 pg/mL. 
Furthermore, the effect of the stimuli on the production of MIP-3α was analysed 
(Fig. 17B). The synthesis of MIP-3α was weakly induced in cells stimulated by IL-1β. In the 
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presence of TNF-α, the release of MIP-3α was comparable to that observed above. However, 
this secretion was lower compared to that of IL-8, indicating that the induction of both 
chemokines is different depending on the stimulus used. Similarly to IL-8, the strongest 
MIP-3α induction was observed in the presence of TNF-α/IL-1β which possibly reflects a 
synergistic effect. 
 
 
Figure 17: IL-8 (A) and MIP-3α (B) production by unstimulated, TNF-α / IL-1β, TNF-α and IL-1β stimulated 
cells. Cells were cultured for 24 h and the amount of both chemokines measured in the culture supernatants by 
ELISA. Results from one of three independent experimental series are shown.  
 
To investigate the effects of extracts on the chemokine production in activated cells, 
TNF-α/IL-1β-stimulated HT29 cells were incubated with varying concentrations of BS or RO 
for 24 hours (Fig. 18). These decreased the synthesis of IL-8 in a dose-dependent manner 
(Fig. 18A). IC50 values for BS and RO were 10.0 and 22.6 μg/mL, respectively. Similar results 
were obtained for MIP-3α, where BS and RO significantly reduced its production (Fig. 18B). 
IC50 values for BS and RO were 2.4 and 3.6 μg/mL, respectively.  
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Figure 18: Effect of BS and RO on the chemokine production 
Levels of IL-8 (A) and MIP-3α (B) in supernatants of TNF-α / IL-1β-stimulated HT29 cells cultured for 24 h in the 
presence of varying concentrations of the extracts. TNF-α / IL-1β-stimulated cells produced 23697 ± 7292 pg/mL 
and 12083 ± 3384 pg/mL of IL-8 and MIP-3α, respectively. The secretion of IL-8 and MIP-3α was determined by 
ELISA. * p < 0.05, ** p < 0.01. Similar data were obtained in 3 independent experiments.  
 
BS and RO modulate mRNA levels of genes involved in inflammatory responses 
During the course of inflammation, a large number of genes are activated. In order to 
determine these changes, the mRNA levels of unstimulated and TNF-α-stimulated cells were 
quantified relative to 18S rRNA using the RT-PCR technology. The influence of TNF-α 
stimulation (Fig. 19) and BS or RO treatment (Fig. 20) was analyzed after 6 hours of culture. 
TNF-α strongly induced IL-8 and TNF-α; moderately up-regulated MIP-3α, MIP-2, GRO-α, 
IP-10, GRO-γ; and only weakly modulated COX-2 and RANTES.  
Furthermore, the effects of BS and RO were analysed (Fig. 20). TNF-α stimulation 
resulted in more than 2000-fold increase of the IL-8 mRNA level relative to unstimulated cells. 
BS and RO diminished this expression, an observation that is consistent with our results of 
produced IL-8. IC50 values for BS and RO were 22.8 and 10.7 μg/mL, respectively, indicating 
that RO was more potent than BS. With regard to TNF-α, activated cells increased its mRNA 
levels ~1000-fold. BS and RO reduced it dose-dependently. MIP-3α mRNA levels rose 
390-fold after TNF-α stimulation. Both BS and RO impeded it in a dose-dependent way, which 
is in line with the protein expression. As to MIP-2, an increase of 400-fold in its mRNA was 
observed after TNF-α stimulation. BS and RO inhibited its expression at each tested 
concentration. For GRO-α gene, TNF-α stimulation increased its mRNA levels to 220-fold and 
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BS dose-dependently reduced it. Conversely, RO only modulated it at 50 μg/mL, representing 
36% of inhibition. In the case of GRO-γ, activated cells inducted its expression to ~70-fold. It 
was dose-dependently impaired in the presence of the extracts. IC50 values for BS and RO 
were 21.5 and 11.7 μg/mL, respectively. The expression of IP-10 was also induced by TNF-α 
stimulation (100-fold increase) and drastically down-regulated by BS. Conversely, RO inhibited 
it at each tested concentration. Cell activation modestly augmented RANTES mRNA levels 
(2.4-fold increase); however, both extracts affected its expression. RO revealed an inhibitory 
effect at all tested concentrations. We also determined the expression of two enzymes 
involved in inflammatory pathways: COX-2 and 5-LOX. COX-2 was 26-fold increased in the 
presence of TNF-α. RO dose-dependently reduced its mRNA level (IC50 23.2 μg/mL) while a 
trend of down-regulation was observed with BS. TNF-α failed to induce the expression of 
5-LOX in this cell line. 
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Figure 19: Effect of TNF-α stimulation on gene expression 
Cells were cultured without or with TNF-α for 6 h. The expression of several genes was determined by quantitative 
RT-PCR and the increase of mRNA levels (relative to unstimulated cells) calculated as described in Material and 
Methods. Representative data of one of two or more independent experiments are shown. 
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Figure 20: Dose-dependent effects of BS 
and RO on several inflammatory genes 
Cells were stimulated with TNF-α for 6 h in 
the presence of varying concentrations of 
indicated extracts. mRNA levels were 
determined relative to unstimulated cells and 
effects of the extracts compared with those of 
EGCG (reference compound). See Figure 4 
for relative amounts of mRNA in 
TNF-α-stimulated cells. * p < 0.05, 
** p < 0.01, *** p < 0.001 when compared to 
stimulated cells. 
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BS and RO extracts target NF-κB DNA binding in intestinal epithelial cells 
Transcription factors of the NF-κB family regulate the expression of genes involved in 
inflammation including proinflammatory cytokines (Barnes and Karin, 1997). We investigated 
the influence of plant extracts on NF-κB activation and its cellular location during in vitro 
inflammation. Nuclear extracts of HT29 cells that were treated with or without TNF-α in the 
presence or absence of 25 μg/mL of BS or RO were isolated after 10 and 20 min of treatment 
and analyzed by EMSA (Fig. 21). Treatment of cells with TNF-α induced NF-κB accumulation 
in the nuclear compartment and thus NF-κB binding activity. BS had no effect on NF-κB 
binding. After 10 min of incubation, RO slightly diminished (~18 ± 1%, two independent 
determinations) NF-κB DNA binding (line 6). RO also reduced NF-κB DNA binding after 
20 min of incubation (~43 ± 9%; line 12). BS and RO alone did not influence NF-κB DNA 
binding activity (lines 3-4 and 9-10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: BS and RO affect NF-κB DNA binding activity in HT29 cells 
Nuclear extracts of unstimulated and stimulated HT29 cells in the presence or absence of BS or RO (25 μg/mL) for 
10 (lanes 1 to 6) and 20 min (lanes 7 to 12) were analyzed by EMSA. Lanes 1 and 7: unstimulated cells; lanes 2 
and 8: TNF-α stimulated cells; lanes 3 and 9: cells treated with BS; lanes 4 and 10: cells treated with RO; lanes 5 
and 11: cells stimulated with TNF-α in the presence of BS; and lanes 6 and 12: activated cells treated with RO. The 
position of the p50/p65 heterodimer DNA complex is represented in the figure as NF-κB. The open circle denotes a 
nonspecific activity binding to the probe and the open arrowhead shows unbound oligonucleotide. Results were 
confirmed in another similar experiment. 
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Influence of extracts on the IκB-α protein expression 
In order to determine the impact of natural extracts on IκB-α protein, cells were 
stimulated and harvested as described above and the amount of IκB-α determined by 
immunoblot analysis (Fig. 22). The effects of substances on the NF-κB pathway have been 
intensively studied in RAW 264.7 cells. For this reason, we used total extracts of this cell line 
stimulated with or without LPS (1 μg/mL) for 20 min as control. Unstimulated RAW cells had 
high amounts of IκB-α in their cytoplasm whereas LPS-stimulated cells retained low quantities 
of this protein, indicating that LPS induces the degradation of IκB-α. In HT29 cells, 
cytoplasmic extracts expressed high quantities of IκB-α protein depending on the treatment. In 
contrast, TNF-α-stimulated cells possessed low amounts of this protein, indicating that TNF-α 
activation resulted in rapid and nearly complete degradation of IκB-α after 10 and 20 min of 
incubation. Similar results were obtained previously (Elewaut et al., 1999). BS or RO alone 
increased IκB-α, suggesting that they could prevent IκB degradation. However, treatment of 
cells with TNF-α in the presence of 25 μg/mL of BS (upper panel Fig. 22) did not reverse the 
effect of TNF-α after 10 and 20 min. This result suggests that in the presence of a stimulus BS 
may not prevent IκB-α degradation. Conversely, activated cells treated with 25 μg/mL RO 
(lower panel Fig. 22) inhibited IκB-α degradation by 43% (after 10 min incubation) and 58% 
(after 20 min incubation) compared to TNF-α alone (16 and 14%, respectively). 
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Figure 22: IκB-α protein analysis in cytoplasmic extracts of unstimulated and stimulated HT29 cells  
Cells were cultured for 10 and 20 min at indicated conditions and lysates prepared as described in Material and 
Methods. The effect of BS and RO is shown in the upper and lower panel, respectively. Immunoblot was performed 
as described above. The blot was further incubated with anti-actin (not shown) and the obtained signal used to 
normalize for the protein load. Numbers below the lanes indicate the % of IκB-α expressed compared to the 
amount detected in unstimulated cells. Similar results were obtained in two independent experiments.  
TNF-α - - -+ + + + +-
LPS - +
Extract 
(25 μg/mL) BS BS BS BS RO
RO RO RO BS ROExtract 
(25 μg/mL)
RAW
IκBα (%) 100 20 174 28 100 23 132 27 37 100 20
100 16 175 57 100 14 111 23 42 100 11
Time (min): 10 20 20
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DISCUSSION 
 
The aim of this study was to investigate whether natural extracts modulate the in vitro 
chemokine production that occurs during intestinal inflammation. Our experimental approach 
dealt with the identification of the anti-inflammatory properties of two extracts, Boswellia 
serrata Roxb and Rosmarinus officinalis L., in stimulated HT29 cells. The effects of these 
extracts were determined at three levels: on the expression of genes induced in inflammation, 
on the NF-κB DNA binding and IκB degradation, and the effect on chemokine synthesis (IL-8 
and MIP-3α). BS and RO markedly diminished the production of IL-8 and MIP-3α and the 
expression of genes involved in the cytokine/chemokine pathways. In addition, RO, but not 
BS, prevented IκB degradation and reduced NF-κB binding activity. These observations 
suggest different modes of action of the extracts on cellular metabolism. 
In the course of inflammation, the activity of intestinal immune cells are altered, leading 
to an abundant expression and secretion of cytokines (e.g. TNF-α and IL-1β) and chemokines 
(Fiocchi, 1997a; Ajuebor and Swain, 2002; Papadakis, 2004). TNF-α and IL-1β are involved in 
the mediation of the inflammatory response and are found in IBD patients, where they 
contribute to the status of chronic inflammation (Dionne et al., 1998; D'Haens, 2003). 
Therefore, these cytokines were chosen to induce an inflammatory state in vitro. Once 
activated, HT29 cells secreted chemokines that are also involved in IBD, IL-8 and MIP-3α. 
IL-8, together with MIP-2, GRO-α and GRO-γ, is a chemokine belonging to the CXC subfamily 
and a potent chemoattractant of neutrophils. These chemokines bind to a common receptor 
CXCR2 (Murphy et al., 2000), and compounds that modulate these chemokines possibly 
impair biological activities dependent on this receptor. Since neutrophils play a major role in 
acute mucosal inflammation because of their ability to produce toxic mediators (e.g. reactive 
oxygen and nitrogen intermediates) in addition to cytokines (Lloyd and Oppenheim, 1992), and 
due to their vast numbers in inflamed intestine (Podolsky, 1991), an excess of these cells 
should be avoided in chronic inflammation. In the present study, BS and RO inhibited the 
production of IL-8 and also down-regulated the expression levels of genes from the CXC 
subfamily (IL-8, MIP-2, GRO-α and GRO-γ). These findings suggest that BS and RO interfere 
with the role of these chemokines in attracting CXCR2-bearing inflammatory cells into the 
inflamed tissue and, therefore, they could ameliorate IBD symptoms.  
MIP-3α, a chemokine of the CC subfamily, is highly expressed in human intestinal 
epithelial cells such as HT29 cells (Izadpanah et al., 2001) and in colonic tissues from IBD 
patients (Kwon et al., 2002). It is responsible for recruiting mainly DC and memory T cells to 
the injured area. Since the T cell response is dysregulated in IBD (Fiocchi, 1998), a control of 
the immigration of these cells is essential to reduce the local inflammation. BS and RO 
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potently reduced the expression and secretion of MIP-3α in activated cells. Consequently, 
both extracts could prevent homing of these cells and, therefore, attenuate the inflammatory 
response. 
TNF-α seriously impaired the epithelial barrier function in HT29/B6, a subclone of 
HT29 cells. This cytokine-induced barrier defect contributes to inflammation due to antigen 
invasion, and to a loss of ions and water into the intestinal lumen, causing diarrhoea (Schmitz 
et al., 1999). Activated HT29 cells strongly up-regulated this cytokine and the presence of BS 
or RO impaired its expression. BS and RO could improve barrier function and interfere with 
diarrhoea in IBD patients. IP-10, a chemokine belonging to the CXC subfamily, is involved in 
the recruitment of monocytes and T cells that express CXCR3. In our study, IP-10 was also 
up-regulated by TNF-α and further influenced by BS and RO, with the latter having a stronger 
effect. This result suggests that BS and RO are also able to affect activities related to the 
receptor CXCR3, reducing the Th-1 immune response. RANTES, like MIP-3α, is a CC 
chemokine and also attracts monocytes, DC and T cells. Upon TNF-α stimulation, RANTES 
was slightly induced and in the presence of BS and RO, its mRNA level was diminished. With 
regard to COX-2, a key-enzyme in the synthesis of prostaglandins, it was induced by TNF-α 
stimulation and inhibited in the presence of BS and RO. COX-2 was reported to be expressed 
in epithelial cells in areas of inflammation in Crohn’s and ulcerative colitis (Singer et al., 1998). 
This observation explains the large amounts of the prostaglandin E2 (PGE2) present in rectal 
dialysates from patients with ulcerative colitis (Lauritsen et al., 1986). Since PGE2 induces 
chloride secretion in epithelial cells, it was suggested that COX-2-related PGE2 generation 
contribute to the diarrhoea observed in IBD (Singer et al., 1998). Presumably, the reduction of 
COX-2 mRNA levels by BS and RO leads to less PGE2, and therefore, reduction of diarrhoea.  
It was shown that the transcription factor NF-κB is involved in the regulation of 
inflammatory processes (Kumar et al., 2004). Since its activation is associated with chemokine 
gene expression, the involvement of the NF-κB pathway was analyzed in HT29 cells. In 
unstimulated cells, NF-κB is retained in the cytoplasm where it is bound by IκB, a complex of 
inhibitory proteins (e.g. IκB-α and IκB-β), which prevent it from entering the nucleus. When 
these cells are activated, IκB is phosphorylated and degraded, allowing nuclear translocation 
of NF-κB (Barnes and Karin, 1997). Our findings indicate that only RO, but not BS, is capable 
of inhibiting IκB-α degradation (as shown in Figure 22) and consequently NF-κB activation, 
suggesting that one mechanism of action of RO is through the NF-κB pathway. By preventing 
IκB degradation, RO impairs the transcription of inflammatory genes and may inhibit early 
steps of inflammation modulating the regulation of multiple proinflammatory genes. 
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In conclusion, we showed in this study that extracts of Rosmarinus officinalis and 
Boswellia serrata attenuate the inflammatory response in HT29 cells by modulating the 
expression of multiple genes, regulating NF-κB activation, and inhibiting IL-8 and MIP-3α 
production. RO is able to interfere with the cytokine/chemokine expression in the NF-κB 
pathway, binding to NF-κB in the nucleus. With regard to BS, this mode of action could not be 
applied because BS affects the expression of NF-κB-regulated genes but it has no influence 
on the activation of NF-κB. Based on these results, BS and RO are good candidates with a 
large panel of effects to use further in in vivo studies of intestinal inflammation. Therefore, we 
provide further evidence that natural extracts are able to reduce inflammation in vitro and, 
thus, may be applicable for the prevention and/or attenuation of intestinal inflammation.  
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ABSTRACT 
 
Curcumin and resveratrol have anti-oxidant and anti-inflammatory effects and seem to 
interfere with inflammatory processes at different levels. In this study, we investigated the 
effect of both curcumin and resveratrol on the expression and production of inflammatory 
mediators such as PGE2 and chemokines in intestinal epithelial cells. In order to trigger an 
“inflammatory” state in vitro, human colon adenocarcinoma cell lines HT29 and T84 were 
stimulated with TNF-α (100 ng/ml) and/or IL-1β (5 ng/ml) in the presence or absence of 
candidate substances. The secretion of IL-8, MIP-3α and PGE2 was measured by ELISA. 
mRNA levels were investigated by quantitative RT-PCR. Stimulation of HT29 cells induced the 
synthesis and secretion of IL-8, MIP-3α and PGE2 whereas in activated T84 cells only IL-8 and 
MIP-3α were released. Curcumin dose-dependently inhibited the synthesis of MIP-3α, but not 
IL-8, in HT29 and T84 cells. Resveratrol did not alter the production of IL-8 in HT29 cells 
whereas it induced the secretion of MIP-3α. In T84 cells, resveratrol diminished MIP-3α 
synthesis whereas no effect was observed on the production of IL-8. Moreover, resveratrol 
and curcumin diminished the generation of PGE2 in HT29 cells. These results were extended 
to the analysis of gene expression in HT29 and T84 cells, however, data were not totally 
corroborated with previous results. Curcumin and resveratrol reduced mRNA levels of IL-8, 
TNF-α, MIP-3α, MIP-2, GRO-α and COX-2. The expression of GRO-γ was down-regulated 
only by curcumin in both cell lines. These data reveal that although the synthesis of IL-8 and 
MIP-3α were differently affected, their expression, in addition to the expression of other 
chemokines, was regulated by both curcumin and resveratrol.  
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INTRODUCTION 
 
Intestinal epithelial cells are the first host to come into contact with invading organisms. 
During bacterial invasion, these cells serve as an early signalling system to adjacent and 
underlying immunocytes. Activation of epithelial cells by pathogens and/or cytokines, such as 
TNF-α and IL-1β, leads to induction of multiple inflammatory mediators responsible for the 
recruitment of inflammatory cells to the injured site (Kagnoff and Eckmann, 1997). In IBD, the 
pathogenesis involves the interaction of host’s genetic constitution, mucosal immunity, and gut 
microflora. Such interactions may lead to a state of normal - “controlled” - inflammation or to 
IBD (Sartor, 1997; Fiocchi, 1998; O'Farrelly, 1998; Shanahan, 2001). 
Recruitment of immunocytes, mainly neutrophils and lymphocytes, to the intestinal wall 
is a central event in the pathogenesis of IBD (Madara, 1997; Izadpanah et al., 2001). As 
described in Chapter 1, chemokines are responsible for the chemoattraction and activation of 
inflammatory cells (Ajuebor and Swain, 2002). IL-8, GRO-α, GRO-γ and MIP-2 belonging to 
the CXC subfamily attract mainly neutrophils whereas MIP-3α, a CC chemokine, chemoattract 
mainly monocytes and lymphocytes. All these molecules are expressed in epithelial cells such 
as HT29 and T84 cells. COX, a bifunctional enzyme with cyclooxygenase and peroxidase 
activities (Zhang et al., 1999), is also involved in inflammatory conditions. The cyclooxygenase 
activity of this enzyme converts arachidonic acid to prostaglandin G2, which is then reduced to 
prostaglandin H2 through its peroxidase activity. PGH2 is converted into other prostaglandins 
by a variety of tissue specific enzymes. COX-1 is constitutively expressed in most tissues and 
generate prostaglandins during the normal physiology, and its expression is not influenced by 
the stimuli (DeWitt and Smith, 1988). The inducible form COX-2 induces the generation of 
prostaglandins, including PGE2, through various stimuli and is involved in normal and 
pathophysiological conditions (Cronstein, 2002). Its expression is induced in colonic epithelial 
cells in IBD (Singer et al., 1998).  
Curcuminoids, responsible for the yellow color of turmeric, are food substances found 
in the root of Curcuma longa Linn, a member of the ginger family Zingaberaceae. They have a 
long history of medicinal use in India and Southeast Asia and exhibit a variety of functions, 
including the anti-inflammatory activity. Curcumin (diferuloylmethane), the major active 
substance, represents approximately 90% of the total curcuminoids present in turmeric 
(Chainani-Wu, 2003). Curcumin has been studied as an alternative treatment in 
gastro-intestinal disorders. In an experimental murine colitis model, curcumin attenuated 
colonic inflammation and prevented death in trinitrobenzene sulphonic acid (TNBS)-induced 
colitis (Sugimoto et al., 2002). Similar results were obtained in another study of TNBS-induced 
colitis (Ukil et al., 2003). In a rat model of colitis, curcumin prevented and cured TNBS-induced 
inflammation by inhibiting the activity of NF-κB (Jian et al., 2005). In another experimental 
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model of colitis, curcumin attenuated dinitrobenzene sulfonic acid (DNB)-induced inflammation 
in mice. Curcumin suppressed the induction of prostaglandin synthesis by inhibiting the 
expression and activity of COX-2 in gastro-intestinal epithelial cells (Zhang et al., 1999). 
Moreover, curcumin was reported to specifically inhibit COX-2 but not COX-1 expression in 
HT29 cells (Goel et al., 2001). It also affected p38 MAPK activity and the NF-κB pathway (Salh 
et al., 2003). Furthermore, curcumin blocked cytokine-mediated NF-κB activation and inhibited 
pro-inflammatory gene expression through the suppression of IKK activity (Jobin et al., 1999). 
Other studies have shown the chemopreventive effects of curcumin in colon cancer (Plummer 
et al., 1999; Churchill et al., 2000; Ireson et al., 2002; van't Land et al., 2004).  
Resveratrol (trans-3,4’,5-trihydroxystilbene), a polyphenol found in various plants, 
including grapes, berries and peanuts, has potent anti-proliferative, anti-carcinogenic, 
anti-oxidant and anti-inflammatory activities. Moderate consumption of red wine which 
contains resveratrol reduced risk of cardiovascular disease (Soleas et al., 1997; Kopp, 1998). 
Resveratrol has also shown an inhibitory effect on the growth of Helicobacter pylori in vitro, a 
gram-negative bacterium associated with the development of peptic ulcers and gastric cancer 
(Mahady and Pendland, 2000). There are a large number of studies demonstrating the 
inhibitory effect of resveratrol on the transcription of COX-2 (Elmali et al., 2005). This could 
explain the anti-cancer and anti-inflammatory activity of resveratrol. In colon cancer cell lines 
such as HT29 cells, resveratrol diminished COX-1 and COX-2 expression (Sovak, 2001). 
Resveratrol was reported to inhibit not only COX but also other metabolites of arachidonic 
acid, including thromboxane B2, 5- and 15-lipoxygenase (Soleas et al., 2001). Moreover, 
resveratrol was able to induce cell cycle arrest, differentiation and apoptosis in tumor cells 
without affecting normal cells and thereby inhibiting tumor progression. The mechanisms of 
action of resveratrol involved in inflammation and cancer include the (1) induction of p53 tumor 
suppressor by stimulating p53 extracellular-signal-regulated protein kinases (ERKs) and p38 
kinase; (2) inhibition of IκB kinase activity by affecting elements of the signalling pathway such 
as the p38 MAP kinase; (3) inhibition of Src tyrosine kinase and protein kinase C (PKC); (4) 
cell cycle arrest, mostly cells in the S phase; (5) inhibition of DNA polymerase (Roemer and 
Mahyar-Roemer, 2002); (6) inhibition of NF-κB-dependent nitric oxide expression and 
production (Cho et al., 2002). 
The present study was undertaken to investigate the anti-inflammatory effects of 
curcumin and resveratrol in TNF-α-activated human colon cancer cell lines, HT29 and T84. 
Their ability on reducing intestinal inflammation in vitro was examined through their action on 
chemokines and inflammatory genes. Our findings clearly demonstrated that curcumin and 
resveratrol have distinct modes of action, operating differently depending on the parameter 
tested.  
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RESULTS 
Impact of phenolic compounds on cell viability 
The cytotoxicity of treatments was determined by measuring the LDH activity in cell 
culture supernatants (Fig. 23). For HT29 cells, the amount of released LDH in different 
treatments was ~60 to ~140 U/L, reflecting < 5% of the total LDH of cells. Furthermore, 
microscopic visualization of cells treated with TNF-α in the presence of high concentrations of 
curcumin (> 50 μM) revealed a large number of death cells. In addition, curcumim increased 
LDH activity, indicating that this substance could affect cell viability. Conversely, cells treated 
with TNF-α in the presence of 50 μM resveratrol did not augment LDH release. With regard to 
T84 cells, a similar profile was observed (~60 to ~100 U/L of LDH release). However, treating 
cells with varying concentrations of curcumin and resveratrol did not significantly affect cell 
viability (Fig. 23B). These findings suggest that high concentrations of curcumin but not 
resveratrol are able to increase LDH activity and therefore alter cell viability. 
 
 
Figure 23: Effects of curcumin and resveratrol on the LDH release by HT29 and T84 cells after 24 hours of 
culture (A). (B) LDH released in T84 cells with or without TNF-α stimulation in the presence of various 
concentrations of curcumin or resveratrol. Cells were stimulated with TNF-α (100 ng/mL) in the presence of 
indicated compunds. Amounts of released LDH are expressed in U/L. Similar data was obtained in two independent 
sets of experiments. 
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Impact of phenolic compounds on IL-8 and MIP-3α secretion  
In order to measure the effect of curcumin and resveratrol on inflammatory parameters, 
cells were stimulated with TNF-α in the presence of varying concentrations of substances for 
10 hours (IL-8 produced after 10 hours was comparible to 24 hours) and the amount of 
released IL-8 determined by ELISA (Fig. 24). Activated HT29 cells produced 
15429 ± 1088 pg/ml of IL-8 and the presence of curcumin or resveratrol did not alter its 
synthesis (Fig. 24A). A similar profile was obtained with T84 cells where cell stimulation 
increased the production of IL-8 to 15376 ± 449 pg/mL, and neither curcumin nor resveratrol 
reduced it (Fig. 24B). 
 
 
Figure 24: Influence of various concentrations of curcumin and resveratrol on the production of IL-8 by 
TNF-α / IL-1β-stimulated HT29 (A) and T84 (B) cells  
Cells were cultured for 10 hours and the amount of IL-8 in culture supernatants measured by ELISA. Results from 
one of three independent experimental series are shown. 
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Figure 25: Effect of curcumin and resveratrol on the production of MIP-3α in HT29 (A) and T84 (B) cells  
Cells were stimulated with TNF-α in the presence of varying concentrations of candidate compounds. Culture 
supernatants were obtained after 24 hours and the amount of MIP-3α measured by ELISA. * p < 0.05. 
Representative data of two independent experiments are shown. 
 
Upon stimulation, HT29 and T84 cells also secreted large amounts of the chemokine 
MIP-3α (8815 ± 628 pg/mL and 10713 ± 629 pg/mL, respectively, as shown in Figure 25). In 
HT29 cells, MIP-3α production was unaltered by resveratrol, whereas curcumin 
dose-dependently inhibited its production (Fig. 25A). Resveratrol moderately impaired the 
amount of secreted MIP-3α while curcumin dose-dependently reduced it in T84 cells 
(Fig. 25B). IC50 values for curcumin and resveratrol were 10.5 and > 50 μM, respectively. 
 
PGE2 generation is affected by resveratrol and curcumin 
The production of PGE2 by HT29 cells was measured to investigate whether phenolic 
compounds affect the in vitro inflammatory response via the arachidonic acid metabolism. To 
this aim, cells were stimulated with TNF-α for 24 hours and the secreted PGE2 was 
determined by ELISA. TNF-α increased the synthesis of PGE2 to 420 ± 40 pg/mL compared to 
unstimulated cells (198 ± 30 pg/mL). These were suppressed by resveratrol in a 
dose-dependent manner and inhibited by curcumin at each tested concentration, indicating 
that resveratrol was more potent that curcumin (Fig. 26). Under the chosen experimental 
conditions, T84 did not produce detectable amounts of PGE2.  
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Figure 26: Curcumin and resveratrol inhibited the secretion of PGE2 in TNF-α-activated HT29 cells  
Cells were stimulated with TNF-α (100 ng/mL) in the presence of varying concentrations of candidate compounds 
for 24 hours. The production of PGE2 was determined by ELISA. * p < 0.05; ** p < 0.01. Similar results were 
obtained in three other series of experiments.  
 
Phenolic substances alter the expression of inflammatory genes in colon cancer cells 
Quantitative reverse-transcription polymerase chain reaction analysis showed 
increased mRNA levels for inflammatory genes, such as IL-8, TNF-α, MIP-3α, MIP-2, GRO-α, 
GRO-γ and COX-2 in TNF-α-activated HT29 cells after 6 hours (Fig. 27). For IL-8 gene, TNF-α 
stimulation resulted in > 780-fold increase of mRNA relative to unstimulated cells. Fifty μM of 
curcumin down-regulated its expression while resveratrol had a weak effect on it. As to TNF-α, 
stimulation of cells with TNF-α enhanced its expression (220-fold increase). Both curcumin 
and resveratrol reduced it, however, the inhibition was more marked by curcumin. MIP-3α 
mRNA levels rose by TNF-α stimulation (280-fold increase). Curcumin and resveratrol 
diminished it, but the effect of curcumin was more accentuated compared to resveratrol’s 
effect. For MIP-2 gene, we observed a 92-fold mRNA increase by TNF-α stimulation. 
Curcumin and resveratrol down-regulated the expression of MIP-2. GRO-α mRNA levels were 
also increased in activated cells (240-fold). Curcumin and resveratrol significantly 
down-regulated its expression. In the case of COX-2 mRNA, TNF-α stimulation resulted in an 
up-regulation of the gene (~ 17-fold increase). The addition of curcumin or resveratrol inhibited 
its expression. For GRO-γ gene, activated cells enhanced its mRNA levels (~ 30-fold 
increase). Curcumin diminished its expression, whereas resveratrol had no major effect. 
Similar profiles were observed in T84 cells, where TNF-α-activated cells increased the 
expression levels of IL-8, TNF-α, MIP-3α, MIP-2, GRO-α, COX-2 and GRO-γ after 6 hours of 
culture (Fig. 28). For IL-8 gene, TNF-α stimulation enhanced its expression 1140-fold. 
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Curcumin and resveratrol (at 50 μM) significantly reduced IL-8 mRNA. These findings were not 
consistent to the observation made for IL-8 production. TNF-α mRNA levels also augmented 
by TNF-α stimulation (400-fold increase). Curcumin and resveratrol inhibited its expression. 
With regard to MIP-3α, an up-regulation of its expression was observed after TNF-α 
stimulation (~250-fold increase). Both curcumin and resveratrol reduced its mRNA level; 
however, the inhibitory effect of curcumin was more accentuated. The expression of MIP-2 
was likewise elevated with TNF-α stimulation (260-fold increase) and similar to data presented 
for HT29 cells, curcumin and resveratrol significantly inhibited its mRNA levels. GRO-α gene 
was 192-fold increased in the presence of TNF-α. Both compounds diminished its expression, 
but curcumin had a stronger effect. In the case of COX-2 gene, TNF-α stimulation resulted in 
approximately 10-fold increase of its mRNA relative to unstimulated cells. Curcumin and 
resveratrol significantly inhibited its expression. GRO-γ mRNA levels rose to 35-fold increase 
by TNF-α stimulation. Curcumin was able to reduce it whereas resveratrol had no effect on its 
expression. 
Figure 27: Curcumin and 
resveratrol modulate genes 
involved in inflammatory 
responses  
Activated HT29 cells were cultured in 
the presence of 50 μM of curcumin 
and resveratrol for 6 hours. The 
effects of candidate substances on 
mRNA expression levels of IL-8, 
TNF-α, MIP-3α, MIP-2, GRO-α, 
GRO-γ and COX-2 were analyzed by 
quantitative RT-PCR. *** p < 0.001. 
Representative data of two 
independent experiments are shown. 
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Figure 28: Effect of curcumin and 
resveratrol on mRNA levels of genes 
involved in inflammation 
T84 cells were stimulated with TNF-α 
(100 ng/mL) in the presence of 50 μM of 
candidate substances and cultured for 
6 hours. The expression of several genes was 
determined by quantitative RT-PCR and the 
increase of mRNA levels (relative to 
unstimulated cells) calculated as described in 
Material and Methods. * p < 0.05; ** p < 0.01; 
*** p < 0.001. Representative data of two 
independent experiments are given. 
 
 
 
 
 
 
 
 
 
The effect of various concentrations of curcumin and resveratrol was examined on 
mRNA levels. In HT29 cells (Fig. 29), TNF-α-induced IL-8 mRNA resulted in > 400-fold 
increase relative to unstimulated cells. Consistent with the RT-PCR data presented above and 
conversely to the protein production data, curcumin inhibited IL-8 mRNA levels only at 50 μM 
while resveratrol reduced it at all tested concentration. For TNF-α gene, we observed an 
increase of 113-fold on its mRNA levels in activated cells. Although a trend of down-regulation 
was observed, curcumin diminished TNF-α expression at 50 μM while resveratrol did not 
affect it. As to MIP-3α, activated cells enhanced its expression (101-fold increase). Curcumin 
reduced it dose-dependently and resveratrol had no major effect on its mRNA levels. MIP-2 
mRNA levels rose by TNF-α stimulation to 104-fold. Curcumin inhibited it in a dose-dependent 
way. Conversely, resveratrol modulated MIP-2 expression at low, and a trend of up-regulation 
was observed at high concentrations. For GRO-α gene, activated cells induced its expression 
to 67-fold. Curcumin dose-dependently diminished its mRNA levels while resveratrol had no 
effect; however, a trend of down-regulation was observed. In the case of COX-2, stimulation of 
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cells with TNF-α resulted in a 10-fold increase of the gene. Curcumin and resveratrol had only 
an effect at high and low concentrations, respectively. 
Similar results were obtained with stimulated T84 cells which also up-regulated 
inflammatory genes. The effect of various concentrations of curcumin and resveratrol were 
analysed after 6 hours culture (Fig. 30). TNF-α/LPS stimulated cells increased the expression 
level of IL-8 mRNA to 936-fold. Curcumin had an inhibitory effect only at high concentrations, 
while resveratrol reduced it at low concentrations. TNF-α mRNA levels drastically rose to 
2419-fold by TNF-α/LPS stimulation. Curcumin dose-dependently inhibited its expression. 
Resveratrol modulated TNF-α mRNA levels in a concentration range up to 25 μM while at 
50 μM, it significantly up-regulated its expression. For MIP-3α gene, activation of cells resulted 
in a 146-fold increase in its mRNA levels. Conversely to the protein data presented above, 
curcumin significantly affected MIP-3α expression only at 50 μM and resveratrol reduced it at 
low concentrations. MIP-2 mRNA levels were augmented in the presence of TNF-α/LPS to 
250-fold. Curcumin diminished its expression at each tested concentration while resveratrol 
significantly reduced it at low, and increased it at high concentrations. Stimulated cells induced 
the expression of GRO-α (184-fold increase) where curcumin modulated it by increasing its 
concentration. Conversely, resveratrol potentially inhibited its expression at low, and slightly 
lowered it at high concentration. With regard to COX-2 gene, TNF-α stimulation increased it 
mRNA levels to 17-fold. Curcumin failed to reduce it expression, although a trend of 
down-regulation was observed. Resveratrol significantly diminished COX-2 mRNA levels at 
each tested concentration. 
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Figure 29: Dose-dependent effects of curcumin and resveratrol on several inflammatory genes in 
HT29 cells  
TNF-α-stimulated cells were treated with various concentrations of curcumin or resveratrol for 6 hours. mRNA 
levels were determined relative to unstimulated cells. * p < 0.05, ** p < 0.01, *** p < 0.001 when compared to 
stimulated cells. 
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Figure 30: Dose-dependent effects of curcumin and resveratrol on gene expression in T84 cells  
Cells were stimulated with TNF-α (100 ng/mL) and LPS (1 μg/mL) in the presence of varying concentrations of 
curcumin or resveratrol for 6 hours. mRNA levels were quantified relative to unstimulated cells. * p < 0.05, 
** p < 0.01, *** p < 0.001 when compared to stimulated cells. 
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DISCUSSION 
 
In this study, we analyzed the anti-inflammatory effect of curcumin and resveratrol on 
the production of chemokines in intestinal inflammation in vitro. Human colon adenocarcinoma 
cells HT29 and T84 were stimulated mainly with TNF-α and the anti-inflammatory effects of 
candidate compounds determined on the expression of several genes involved in 
inflammatory processes and on the production of chemokines (IL-8 and MIP-3α) and PGE2. 
Curcumin and resveratrol had no effect on the production of IL-8, however, an effect was 
observed on the gene expression. Furthermore, the production of MIP-3α was strongly 
affected by curcumin whereas a weak down-regulation of its expression was obtained with 
both curcumin and resveratrol. The generation of PGE2 was also inhibited by curcumin and 
resveratrol. These observations give insight into the different mode of action of phenolic 
compounds on colon cancer cell lines.  
During intestinal inflammation, a large number of inflammatory cells, including 
neutrophils and lymphocytes, infiltrate the mucosa, lamina propria, and the crypts. 
Transmigration of neutrophils across the epithelium leads to a structural and functional 
compromise in epithelial integrity and alteration in barrier function (Madara, 1997; Nusrat et 
al., 1997). Therefore, compounds that are able to block neutrophil migration can ameliorate 
inflammation. Curcumin and resveratrol did not inhibit the production of IL-8 in epithelial cells, 
however, a weak effect was observed on the gene level where curcumin and resveratrol 
down-regulated IL-8 mRNA only at high concentration. Epithelial cells also express different 
chemokines belonging to the same CXC subfamily as IL-8, including GRO-α, GRO-γ and 
MIP-2 (van Deventer, 1997). Since they also recruit neutrophils, an inhibitory effect on their 
expression results in a lesser mucosal neutrophil immigration. In addition, IL-8, GRO-α, GRO-γ 
and MIP-2 share the same receptor CXCR2. Although curcumin and resveratrol did not inhibit 
the production of IL-8, we suggest that they might affect neutrophil attraction through the 
down-regulation of GRO-α, GRO-γ and MIP-2.  
Furthermore, lymphocyte chemoattraction is associated with increased levels of 
MIP-3α. Human intestinal epithelial cells regulate the expression of this chemokine which is 
responsible to recruit APC (e.g. DC) and memory T cells in addition to develop the host 
adaptive immune response (Izadpanah et al., 2001). An increase in the production of this 
chemokine was found in primary epithelial cells isolated from patient with IBD, suggesting that 
“inflamed” epithelial cells produce and secret MIP-3α which attracts CD4+ T lymphocytes and 
immature DCs to the inflamed epithelium (Kwon et al., 2002). Compounds acting on this level 
are able to reduce the recruitment of lymphocytes, and thus, inflammatory processes involved 
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in IBD. Curcumin and resveratrol differ in their mode of action on the production of MIP-3α. 
While resveratrol had no effect on (T84), or rather enhanced (HT29), the MIP-3α production in 
epithelial cells, curcumin inhibited it in both cell lines tested. With regard to curcumin, our 
results suggest that inhibiting MIP-3α it may affect the lymphocyte infiltration, meliorating 
inflammatory symptoms.  
Moreover, the potency of curcumin and resveratrol to reduce the generation of PGE2 
was analyzed. As described before, PGE2 is expressed by epithelial cells in response to a 
pathogen or TNF-α stimulation (Singer et al., 1998). In IBD where the level of this cytokine is 
increased (D'Haens, 2003), TNF-α induces the generation of COX-2-dependent PGE2 which, 
in turn, is responsible for the epithelial chloride secretion, and thereby, IBD-associated 
diarrhea (Singer et al., 1998). In our study, curcumin and resveratrol down-regulated COX-2 
expression (at 50 μM) in HT29 and T84 cells, and PGE2 secretion in HT29 cells. By reducing 
COX-2-dependent PGE2 production, curcumin and resveratrol may ameliorate diarrhea 
present in CD. Moreover, we speculate about the possibility that curcumin and resveratrol 
could inhibit chloride secretion through the inhibition of TNF-α. 
In conclusion, we showed that natural substances are able to attenuate inflammation in 
intestinal epithelial cells by modulating the expression of pro-inflammatory genes and MIP-3α 
production. Based on the obtained results, curcumin was more potent than resveratrol with a 
larger panel of effects. The effects of resveratrol on intestinal epithelial cells were not 
consistent in this study. Discrepancies between chemokine production and gene expression 
were observed. Furhter analyses should be done in order to clarify its effect on epithelial cells. 
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GENERAL DISCUSSION 
 
The intestinal epihtelium is normally exposed to a large number of microorganisms 
(e.g., bacteria, viral agents) and diverse types of nutrients. The latter are able to cross the 
interface between the gut lumen and the intestinal mucosa, while the crossing of potentially 
injurious agents is effectively and efficiently prevented. Such an event is only possible due to 
the presence of highly sensitive intestinal immune system which regulates the intestinal host 
defense and supports epithelial cells in their primordial function as maintainers of the epithelial 
integrity. Once this regulatory balance between pathogens, epithelial cells and immune system 
is disturbed, nonspecific stimulation and activation lead to the release of increased amounts of 
potent destructive molecules, leading to tissue injury (MacDermott, 1994).  
One of the worldwide most prevalent intestinal disorders is IBD, a chronic disease 
arising from a dysregulated immune response. Several immune cells including macrophages, 
T and B cells are present in high amounts in the inflamed mucosa producing inflammatory 
mediators such as cytokines, chemokines, prostaglandins in addition to immunoglobulins (e.g., 
IgA) (MacDermott, 1994). Although different cytokines are present in IBD, TNF-α still the most 
relevant. It is found through the entire course of the disease and induces the secretion of a 
variety of proinflammatory cytokines and chemokines from epithelial and mononuclear cells 
(Sands, 2004), thus enhancing the inflammatory response. Since several factors could be 
responsible for the onset of IBD (e.g., genetic, environmental, bacteria invasion) (Fiocchi, 
1998), actual therapeutic drugs, including corticosteroids, aminosalicylates, 
immunomodulators and monoclonal antibodies (anti-TNF) are used only to attenuate 
symptoms and/or relapses of the disease. In addition, the use of such medicaments lead to 
marked site effects (Yang and Lichtenstein, 2002).  
Natural substances with anti-inflammatory properties could assist aforementioned 
therapies by reducing inflammatory processes and delaying the relapse of the disease. In 
addition, they could be useful in the prevention of IBD. In this thesis, the anti-inflammatory 
effects of three natural compounds (EGCG, curcumin and resveratrol) and two plant extracts 
(BS and RO) were analysed in an in vitro model of intestinal inflammation (chemical structure 
of the substances are shown in Figure 31). Human colon adenocarcinoma cell lines, HT29 and 
T84, were used as a human in vitro cell culture model with close resemblances to the human 
intestinal epithelium. Although several groups, including ours, have used these cells as in vitro 
model for intestinal inflammation, it should be emphasized that both cell lines have a 
neoplastic origin which differ from human intestinal epithelium features, e.g., neoplastic cells 
growth faster than normal cells and are more sensitive to toxins.  
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Figure 31: Chemical structure of tested substances 
EGCG: http://www.biochemj.org/bj/368/0695/bj3680695.htm;  
Boswellic acid: http://www.itmonline.org/arts/myrrh.htm;  
Curcumin: http://parasitology.informatik.uni-wuerzburg.de;  
Rosmarinic acid: http://www.alexis-corp.com;  
Trans-resveratrol: http://www.wine.yamanashi.ac.jp/biofunctional/biofunctional.html. 
 
The effects of candidate substances were determined at various levels: (1) on the 
expression of genes induced by TNF-α; (2) on the secretion of metabolites that are associated 
with inflammation; and (3) on the protein expression. Table 5 summarizes the 
anti-inflammatory effect of tested compounds in stimulated HT29 and T84 cells.  
 
 
 
 
 
 
 
 
rosmarinic acid
(Rosmarinus officinalis)
trans-resveratrol
curcumin
(-)-epigallicatechin-3-gallate (EGCG)
boswellic acid
(Boswellia serrata)
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Table 5: Summary of the effects of candidate substances in intestinal inflammation in vitro. 
 
In the course of intestinal inflammation, several mediators including cytokines and 
chemokines are expressed and released by different cell types including immunocytes and 
epithelial cells. Cytokines (e.g., TNF-α and IL-1β) are responsible to activate and induce the 
synthesis of chemokines in epithelial cells (Dionne et al., 1998; Sands, 2004) which then 
chemoattract leukocytes and lymphocytes to the injured tissue (Ajuebor and Swain, 2002). 
Data presented in this thesis demonstrate that the synthesis of two important chemokines, IL-8 
Process Acronym HT29 T84
EGCGa BSb ROb Curca Resa EGCGa Curca Resa
Viability Ø † Ø † Ø Ø Ø Ø
Gene expression IL-8 +++ ++++ ++++ +++ + + ++ +
TNF-α +++ +++ +++ +++ ++ ++ ++++ +
MIP-3α +++ ++++ +++ ++++ + +++ +++ ++
MIP-2 +++ ++++ +++ +++ ++ ++ +++ ++
GRO-α +++ ++++ ++ +++ ● + +++ ++
GRO-γ ++ +++ +++ +++ ± ++ +++ ±
IP-10 ++ ++ ++++ ND ND ± ND ND
RANTES ++ + +++ ND ND ND ND ND
COX-2 ++ ++ +++ +++ ++ ++ ++ +
5-LOX ± ± ± ND ND ND ND ND
Metabolite PGE2 ♣♣♣ ND ND ♣♣ ♣♣♣  -  -  -
IL-8 ♣♣♣  ► ♣♣♣  ► ♣♣♣  ► ♣ ♣ ♣♣♣  ► 
MIP-3α ♣♣♣♣  ▼ ♣♣♣♣  ▼ ♣♣♣♣  ▼ ♣♣  ▲ ▼ ♣♣♣♣ ♣♣♣  ► ♣♣  ▲ 
Protein IκBα ND 28%c; 27%d 57%c; 42%d ND ND ND ND ND
NF-κB p65 ND 93%c; 116%d 88%c; 109%d ND ND ND ND ND
Legend:
ND not determined
IC50 inhibitory concentration of 50%
Curc curcumin
Res resveratrol
a 50 μM
b 50 μg/mL
c 25 μg/mL 10 min
d 25 μg/mL 20 min
Ø no cytotoxic LDH activity < 10%
† moderate cytotoxic LDH activity 10 - 20%
++++ total inhibition gene expression > 90%
+++ strong inhibition gene expression 61 - 90%
++ moderate inhibition gene expression 31 - 60%
+ weak inhibition gene expression 5 - 30%
± no effect gene expression < 5%
● gene induction ~100%
♣♣♣♣ total inhibition metabolite > 90%
♣♣♣ strong inhibition metabolite 61 - 90%
♣♣ moderate inhibition metabolite 31 - 60%
♣ weak inhibition metabolite 5 - 30%
- no production metabolite < 5%
▼ IC50 < 6 μM metabolite
► IC50 between 10 - 20 μM metabolite
▲ IC50 > 50 μM metabolite
weak increase metabolite 20 - 25%
strong increase metabolite > 90%
strong IκBα degradation
moderate to weak IκBα degradation
amount of NF-κB in the nucleus
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and MIP-3α, is strongly inhibited by EGCG (IC50 of 10.7 and 2.0 μM, respectively), BS (IC50 of 
11.6 and 2.4 μg/mL, respectively) and RO (with IC50 of 20.0 and 3.6 μg/mL, respectively) in 
HT29 cells. Curcumin and resveratrol moderately to weakly affected chemokine production. 
Interestingly, resveratrol drastically increased the secretion of MIP-3α in these cells, an 
observation which can not be explained by altered cell viability. In T84 cells, EGCG had a 
similar effect on the chemokine production. Furthermore, curcumin strongly inhibited MIP-3α 
production with an IC50 of 10.5 μM while a weak effect was observed on the IL-8 synthesis. 
With regard to resveratrol, a moderate to weak effect was observed on the chemokine 
production. Although EGCG, BS and RO exhibit similar effects on the chemokine secretion, 
their chemical structure differ from each other. However, their bioavailability could be similar. A 
similarity in the structure was observed between rosmarinic acid, the active substance of RO, 
and curcumin, however, the former presents a caffeoyl ester group which may be responsible 
for its stronger inhibitory effect. A common feature between these substances is their 
anti-oxidant properties which might explain most of the effects, a statement based on a large 
number of literature data. Moreover, these results were corroborated by gene expression 
profiling where EGCG, BS, RO, and curcumin showed potent effects on the expression of 
genes of the inflammatory pathway, especially those of the cytokine/chemokine network (IL-8, 
TNF-α, MIP-3α, MIP-2, GRO-α, GRO-γ, and IP-10). In HT29 cells, EGCG, BS, RO, and 
curcumin at high concentrations showed similar effects on the expression of inflammatory 
gene. With regard to resveratrol, it had a weak or no effect on related genes. In T84 cells, 
curcumin had the strongest effect while EGCG and resveratrol moderately affected the 
abovementioned genes. We infer that the differences observed between HT29 and T84 reflect 
different origin of the cells (see Chapter 1).  
As described in Chapters 1 and 3, EGCG, BS, and RO strongly affected chemokines 
belonging to the CXC family and responsible to recruit leukocytes (mainly neutrophils) to the 
injured tissue, i.e. IL-8, GRO-α, GRO-γ, and MIP-2. These target the receptor CXCR2 (Murphy 
et al., 2000). Furthermore, EGCG, BS, and RO also inhibited MIP-3α, a member of the CC 
subfamily involved in the chemoattraction of lymphocytes, DC and monocytes to the “inflamed” 
tissue. It is a ligand to the chemokine receptor CCR6 (Murphy et al., 2000; Izadpanah et al., 
2001). Data presented in this thesis suggest that EGCG, BS, and RO impair the recruitment of 
immunocytes to the injuried area by affecting biological activities mediated through CXCR2 
and CCR6. Analyses of the expression of these receptors on epithelial cells are needed to 
clarify these hypotheses. 
Recently, Wallace and Devchand reviewed the role of COX-2 in gastro-intestinal 
mucosal defense. COX-2 was rapidly and substantially up-regulated after induction of colitis in 
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a rat model which was accompanied by a sharp increase of PGD2, an anti-inflammatory 
prostaglandin that dampened granulocyte infiltration. In agreement with this, it was reported 
that treating experimental colitis with selective COX-2 inhibitors during the early phase leads 
to enhanced granulocyte infiltration and further ulcer development (Wallace and Devchand, 
2005). We observed that the expression of COX-2 was elevated in the presence of the 
stimulus. However, at high concentrations all substances tested inhibited its expression. 
Moreover, since COX-2 is a key enzyme involved in the generation of PGE2, the effect of 
candidate compounds on PGE2 production was analysed. A moderate to strong inhibition was 
observed in TNF-α-activated HT29 cells in the presence of EGCG, curcumin and resveratrol, 
confirming the abovementioned effects on the COX-2 expression. BS and RO were not tested 
in this assay and T84 cells did not produce detectable amounts of PGE2. As previously 
described, EGCG, curcumin and resveratrol inhibited COX-2 which explained its effect on both 
COX-2 and PGE2. As reviewed by Wallace, COX-2 is necessary for the GI mucosal defense, 
however, in a limited amount. Candidate substances reversed TNF-α-induced COX-2 
expression and further PGE2 generation in epithelial cells, suggesting that these could be an 
undesired property of the substances. 
The activation of NF-κB is an important step for the transcription of inflammatory 
genes, including chemokines. As described in Chapter 3, in unstimulated cells, NF-κB is 
retained in the cytoplasm bound to IκB. Upon activation, IκB is phosphorylated and degraded 
allowing NF-κB dissociation and translocation into the nucleus. We showed that BS did not 
prevent IκBα degradation and did not impair the translocation of NF-κB into the nucleus. On 
the other hand, RO reduced the IκBα degradation (57% and 42% after 10 and 20 min, 
respectively); however, no effect was observed on the NF-κB translocation. Since RO affected 
NF-κB DNA binding (as shown in our EMSA results), we infer that RO may be able to 
covalently alter NF-κB binding sites, indicating that one mechanism of action of RO is through 
the NF-κB pathway. 
Moreover, we presented in Chapter 2 that EGCG also modulates the expression of 
multiple genes involved in specific pathways, including those of the immune response, 
apoptosis, cell adhesion, ECM, growth signaling and cell cycle. Genes of the immune 
response which were up-regulated with TNF-α and involved in the perpetuation of 
inflammation were inhibited by EGCG, such as cytokines and chemokines. EGCG also 
regulated genes of the NF-κB pathway such as IκBα which would not be degradated by the 
proteasome, maintaining NF-κB in the cytoplasm. Genes involved in apoptosis were either up- 
or down-regulated in the presence of EGCG. The effects of the latter were heterogeneous, in 
one hand inhibiting genes of the TNF/TNFR1 signaling and, in the other hand, affecting death 
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receptors and further the caspase cascade. We suggest that in order to balance the immune 
system, EGCG may act in cell surveillance, increasing Bcl3 and MCL1; and apoptosis by 
up-regulating death receptors such as DR5 and DR6. Furthermore, genes involved in cell 
adhesion were also regulated by EGCG. Our results infer that EGCG is able to affect 
immunocyte infiltration, and thus, ameliorate inflammation through two ways: inhibiting the 
production of chemokines, and reducing the expression of adhesion molecules such as 
ICAM-1, ICAM-4. In addition, EGCG may increase mucosal barrier functions by augmenting 
the quantity and/or activity of gap- and tight-junctions between adjacent epithelial cells. 
Moreover, genes responsible for tissue repair and remodeling were elevated by EGCG in 
activated cells, including LAM5 and collagen. In summary, these data clearly indicate that 
EGCG, with its heterogeneous effect on several cellular processes, influences specific sets of 
TNF-α-inducible genes. Beside the anti-inflammatory effects, EGCG may be useful in the 
regulation of lipid metabolism as well as in cancer therapies. A possible model for the 
mechanism of action of EGCG, based on DNA microarray data, is out-lined in Fig. 32. 
Although an array of effects were seen in the gene level in cells treated with EGCG, these 
data should be further analysed by RT-PCR and protein expression in order to confirm our 
statement. 
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Legend: 
Figure 32: Possible sites of 
action of EGCG in HT29 cells 
EGCG interferes with the 
binding of TNF-α to TNFR1. 
Moreover, EGCG possibly 
modulates genes between 
TRADD and FADD. Apoptosis 
is impaired by EGCG through 
the regulation of the caspase 
cascade. EGCG affects Jun 
kinase (JNK) and PKC 
pathways. EGCG may also 
interfere with the PI(3)K kinase 
pathway, which would not lead 
to the activation of IκB kinases 
(IKK). EGCG induces the expression of MEKK1, which activates IKK, leading to IκB degradation and further NF-κB 
activation. EGCG directly inhibits IκBα expression. Finally, EGCG may be able to covalentely bind to the NF-κB in 
the nucleus. NF-κB can not bind to its promoter region which would not activate the expression of inflammatory 
genes. 
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Taken together, the findings presented in this thesis provide an extension of the mode 
of action of phenolic substances in intestinal inflammation in vitro. EGCG, BS, RO, and 
curcumin exert their anti-inflammatory effects by inhibiting the expression and production of 
chemokines and reducing the generation of PGE2 (Fig. 33). Furthermore, some specific 
pathways are affected by EGCG and RO, including TNF/TNFR1 and NF-κB, respectively. 
More experiments are needed to rule out the effect of EGCG on NF-κB pathway in the protein 
level. Based on these results, phenolic compounds have the ability to interfere with in vitro 
intestinal inflammation. Obviously, in vivo studies are mandatory to corroborate this statement. 
Provided these prove to be conclusive, phenolic substances will be further applicable for the 
prevention and attenuation of intestinal inflammatory disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Model for the mode of action of phenolic compounds and plant extracts in the “inflamed” 
intestinal environment 
Dysregulation in the immune response leads to epithelia injury which facilitates the penetration of microbial 
antigens into the mucosa. Intestinal macrophages initiate the synthesis of TNF-α and IL-8. The former stimulates 
T-cells to produce IFN-γ, and together, they diminish mucosal barrier functions. TNF-α also activates epithelial cells 
to produce IL-8 and MIP-3α. High amounts of IL-8 present in the mucosa leads to the recruitment of PML while 
increased levels of MIP-3α recruit basically lymphocytes from the circulation. EGCG, BS, RO, and curcumin inhibit 
MIP-3α (as shown in light green) while only EGCG, BS, and RO reduce the production of IL-8 (shown in dark 
green). It still unclear whether phenolic compounds could also impair the production of TNF-α, although evidences 
from gene expression data would suggest that they do. It also remains unknown if these substances could directly 
act on microbial antigens. 
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OUTLOOK 
 
Gene expression profiling has permitted us to extend our view of the possible effects of 
EGCG. Although a speculation about the mechanism of action of EGCG has been ilustrated, 
to complete the knowledge of signaling pathways and to corroborate findings presented in this 
thesis, genes found to be highly or even not regulated with the stimulus and the treatment 
should be further analyzed by RT-PCR and also protein expression. Moreover, a 
time-dependent gene chip experiment could provide data on early, intermediate, and late 
effects of the substances, delivering more information about the kinetics of specific genes and 
how they are influenced by the compounds. 
The effect of EGCG on genes involved in the NF-κB pathway was quite promising. 
However, we could not conclude whether these effects would also be observed on the protein 
level. Studies regarding protein degradation and phosphorylation would give new insights for 
the action of EGCG. 
Overall, there are relatively few in vivo data about the anti-inflammatory effects of 
phenolic substances in intestinal inflammation. In order to use these substances in the clinic, 
in vivo or ex-vivo studies are necessary. Furthermore, efficacy studies and “molecular safety” 
approaches regarding the effects of such substances in other tissues (e.g. liver) should also 
be addressed. 
Since our findings presented in Chapter 3 refered to the effect of whole plant extracts, 
the isolation and further purification of their active compounds should be taken in 
consideration. Further investigations on their efficacy and anti-inflammatory activity will give a 
new insight in the intestinal inflammation field. 
As described in Chapter 4, discrepancies to published data were observed regarding 
the effects of curcumin and resveratrol on the chemokine production and gene expression 
profile. The reason for these differences is unclear, but they could be due to different 
experimental conditions (e.g. source of cell line, origin of substances, condition of stimulation). 
These need to be established in additional experiments.  
Additionally, preliminary studies on transporter genes identified EGCG and curcumin as 
modulators of ABCB1 and ABCC2. The presence of EGCG or curcumin seem to affect the 
efficacy in importing or exporting xenobiotics to the lumen as well as to prevent the import or 
export of compounds such as chemotherapeutics into the cell. Additional studies are needed 
in order to clarify these findings also in the protein level. 
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It may be difficult for humans to consume sufficient quantities of phenolic compounds 
from their normal diets. This gives the reason for enhanced supplementation by fortifying 
foods or using supplements. Animal studies and human trials would indicate a reasonable 
safety profile that will help to define and calculate the ideal dose for a chemically synthesized 
or highly purified “natural drug” of known quality. 
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SUMMARY 
 
Natural plant extracts and their isolated phenolic substances have been shown to exhibit 
several functions including the anti-inflammatory activity in various tissues. EGCG, curcumin 
and resveratrol have been identified as possible anti-inflammatory agents while little is known 
about extracts of Boswellia serrata (BS) and Rosmarinus officinalis (RO). 
In this thesis project, several methods were applied in order to identify the anti-inflammatory 
effects of aforementioned substances and extracts in “inflamed” intestinal epithelial cells. The 
colon cancer cell lines, HT29 and T84, were stimulated with TNF-α in the presence of various 
concentrations of EGCG, BS, RO, curcumin and resveratrol. Their effects were analyzed at 
different levels: (1) on the expression of multiple genes involved in inflammatory responses; 
(2) on the generation of metabolites such as PGE2, and production of chemokines (e.g., IL-8 
and MIP-3α); (3) and on the protein expression. The expression of genes was determined by 
quantitative RT-PCR and microarray technology. The production of IL-8, MIP-3α and PGE2 
were measured by ELISA. The expression of proteins belonging to the NF-κB pathway was 
analyzed by immunoblots. In addition, NF-κB DNA binding was carried out using EMSA. 
Treatment of activated cells with EGCG, BS, RO, curcumin and resveratrol reduced the 
expression of most genes related to the inflammatory response of HT29 and T84 cells. 
Furthermore, EGCG, curcumin and resveratrol diminished the generation of PGE2 in 
HT29 cells. In addition, the secretion of IL-8 and MIP-3α were dose-dependently inhibited by 
candidate compounds in HT29 cells. EGCG reduced the production of these chemokines also 
in T84 cells while curcumin and resveratrol only diminished MIP-3α synthesis. Moreover, the 
expression of IκBα and NF-κB p65 were analyzed in HT29 cells. BS was not able to prevent 
IκBα degradation and subsequent NF-κB translocation whereas RO interfered with IκBα 
degradation, however, it did not impede the activation of NF-κB. Additionally, RO reduced 
NF-κB DNA binding tested by EMSA. 
Collectively, the presented data show that phenolic substances or whole plant extracts have 
the capacity to attenuate inflammatory features by modulating genes involved in inflammatory 
responses; by reducing the chemoattraction of immunocytes through the inhibition of IL-8 and 
MIP-3α; and by affecting specific pathways involved in inflammation such as the NF-κB. 
Furthermore, phenolic compounds might have a preventive and/or therapeutic utility in chronic 
inflammation such as IBD, and therefore, they should be further analyzed in in vivo studies to 
consolidate these findings. 
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ZUSAMMENFASSUNG 
 
Natürliche Pflanzen-Extrakten und deren phenolische Substanzen haben verschiedene 
Funktionen einschliesslich entzündungshemmende Effekte in verschiedene Gewebe. 
Während EGCG, Curcumin und Resveratrol als mögliche anti-inflammatorische Substanzen 
nachgewiesen wurden, ist über Boswellia serrata (BS) und Rosmarinus officinalis (RO) 
Extrakten wenig bekannt.  
In diese Dissertation wurde verschiedene Methoden angewendet, um die 
entzündungshemmenden Effekte der erwähnten Substanzen und Extrakten in 
Darmepithelzellen zu identifizieren. Die Darmkrebs-Zelllinien HT29 und T84 wurden mit TNF-α 
zusammen mit verschiedenen Konzentrationen von EGCG, BS, RO, Curcumin und 
Resveratrol stimuliert. Ihre Effekte wurden auf unterschiedlichen Ebenen analysiert: (1) 
Expression der mehrfachen Gene die in entzündliche Antworten beteiligt werden; (2) Bildung 
der Stoffwechselprodukte wie PGE2, und die Freisetzung von Chemokinen (z.B. IL-8 und 
MIP-3α); (3) und Proteinexpression. Die Expression der Gene wurde durch quantitative 
RT-PCR und DNA microarray Technologie evaluiert. Die Produktion von IL-8, MIP-3α und 
PGE2 wurde durch ELISA gemessen. Die Expression der Proteine, die zum NF-κB Pathway 
gehören, wurde durch Immunoblots analysiert. Zusätzlich wurde auch die NF-κB DNA 
Bindung durch EMSA geprüft. Aktivierte Zellen, die mit EGCG, BS, RO, Curcumin und 
Resveratrol behandelt wurden, haben die Expression der meisten analysierten Entzündungs-
Gene in HT29 und T84 reduziert. Ausserdem haben EGCG, Curcumin und Resveratrol die 
Bildung von PGE2 in HT29 Zellen vermindert. Zusätzlich wurde die Freisetzung von IL-8 und 
MIP-3α dosis-abhänging durch die getesteten Substanzen gehemmt. EGCG verringert die 
Produktion dieser Chemokine auch in den T84 Zellen, während Curcumin und Resveratrol nur 
die MIP-3α Freisetzung vermindern. Weiterhin wurde auch die IκB-α Expression in HT29 
analysiert. BS konnte den IκB Abbau und nachfolgende NF-κB Translokation nicht verhindern, 
während RO störend auf den IκB Abbau wirkte. RO konnte die NF-κB DNA Bindung 
reduzieren. 
Die in dieser Arbeit dargestellten Daten zeigen, dass phenolische Substanzen oder Gesamt-
Extrakten anti-inflammatorische Eigenschaften aufweisen, indem sie die Gene, die in 
entzündliche Antworten betroffen sind, modulieren; die Chemoattraktion von Immunocyten 
durch die IL-8 und MIP-3α Inhibition reduzieren; und spezifischen Pathways beeinflussen, die 
in Entzündung mit eingezogen sind wie NF-κB. Somit können phenolische Substanzen eine 
vorbeugende und/oder therapeutische Wirkung in chronischen Entzündungen wie IBD haben. 
Diese Befunde soltten nun durch in vivo Studien bestätigt werden.     
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